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Cognitive Rehabilitation for Cocaine Use Disorder 
Rajkumar Kiran Kalapatapu 
Abstract 
Brief Statement of the Problem: Effectively treating cognitive impairment as part of a 
comprehensive treatment plan for adults with cocaine use disorder (CUD) could potentially 
improve important clinical outcomes, such as abstinence, quality of life, and treatment 
completion. Because existing models of cognitive rehabilitation have yielded small to medium 
effect sizes in improving cognition in CUD, newer models of cognitive rehabilitation are needed 
to improve cognition more effectively in CUD.  
Description of the Methods and Procedures Used to Gather Data: This dissertation 
describes a pilot 12-week, randomized, parallel group outpatient study of treatment-seeking 
adults with CUD (age 18-65) who were mild-to-moderately cognitively impaired and dissatisfied 
with their quality of life. Participants were randomized to a “Cog-Rehab” arm (drug counseling + 
occupational therapy-based cognitive rehabilitation), or to a “Control” arm (drug counseling + 
psychoeducation/computer exercises). 
Condensed Summary of the Findings: Study participants had a mean age of 57.5 years (SD 
5.8), 30 (96.8%) were male, 19 (61.3%) were Black, 12 (38.7%) were White, 6 (19.4%) were 
Latino, 15 (48.4%) were single, and had a mean education of 12.8 years (SD 1.4). Some 
significant between-group effect sizes were found for certain neurocognitive measures (favoring 
Cog-Rehab arm: attentional bias 1.0 attention 0.7, visual memory 0.8, executive function 1.0) 
and one functional assessment (favoring Cog-Rehab arm: Drug User Quality of Life Score 0.8). 
This study was feasible, acceptable, and provides preliminary evidence for efficacy based on 
effect sizes. MET-R performance was significantly associated only with the overall impulsivity 
neurocognitive domain (adjusted coefficient 0.8, 95% CI 0.2 to 1.3) on a neurocognitive battery. 
The MET-R may be uniquely measuring the domain of impulsivity that is not captured by 
traditional neurocognitive testing. 
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Chapter 1 Abstract 
Background: As cognitive impairment moderates clinical outcomes in adults with cocaine use 
disorder (CUD), effectively treating cognitive impairment as part of a comprehensive treatment 
plan for CUD could potentially improve important clinical outcomes, such as abstinence, quality 
of life, and treatment completion. Because existing models of cognitive rehabilitation have 
yielded small to medium effect sizes in improving cognition in CUD, newer models of cognitive 
rehabilitation are needed to improve cognition more effectively in CUD.  
Aims: Practitioners in the occupational therapy (OT) field work on improving the function of 
various cognitively impaired populations (e.g., stroke, traumatic brain injury, schizophrenia) by 
using cognitive-adaptation techniques to enhance cognition in daily quality of life/function. OT 
can address the cognitive and problem-solving deficits that lead to a breakdown in daily life 
skills. A model of OT-based cognitive rehabilitation in CUD may strongly improve cognition, 
ultimately improving important clinical outcomes. The overall project aims were to examine the 
improvement in cognition, examine the improvement in cocaine abstinence, and examine the 
improvement in daily quality of life/function from a novel model of OT-based cognitive 
rehabilitation. 
Methods: This paper describes the protocol for a pilot 12-week, randomized, parallel group 
outpatient study of treatment-seeking adults with CUD (age 18-65) who were mild-to-moderately 
cognitively impaired and dissatisfied with their quality of life. Participants were randomized to a 
“Cog-Rehab” arm (drug counseling + OT-based cognitive rehabilitation), or to a “Control” arm 
(drug counseling + psychoeducation/computer exercises). Because this study was a pilot trial, 
the initial goals were to assess feasibility of enrollment and acceptability of all study procedures 
by participants. 
Discussion: This manuscript describes the protocol for a pilot study that will assess the 
feasibility and acceptability of a novel approach for improving cognition in adults with CUD and 
cognitive impairment. CUD remains a significant public health problem in the U.S., and cognitive 
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impairment moderates clinical outcomes in CUD. Integrating OT-based cognitive rehabilitation 
in a comprehensive treatment plan for CUD could have a direct and significant positive impact 
on the public health burden of this population.  
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Chapter 1 Main Body 
INTRODUCTION 
Cocaine use disorders (CUDs) remain a significant U.S. public health problem [1, 2]; in 
2014, there were an estimated 1.5 million current (past-month) cocaine users aged 12 or older, 
and data from the 2011 Drug Abuse Warning Network report show that one in three drug 
misuse or abuse-related emergency department visits (40 percent) involved cocaine. Having a 
diagnosis of CUD is associated with cognitive impairment [3-8] (medium to large effect sizes [9]) 
in the domains of psychomotor speed [10-12], memory [10, 13-18] (up to 47% of patients with 
CUD [19]), attention/concentration [13, 20-25], and executive function [26-30]. One study 
showed that 30% of those with CUD and even 12% of recreational cocaine users exhibited 
clinically relevant global cognitive impairment [31, 32]. Cognitive impairment in those with 
substance use disorders (SUDs) [33-37] is associated with relapse [38, 39], lower likelihood of 
treatment completion [40-44], lower motivation [45], and worse quality of life [46, 47]. As 
cognitive impairment moderates clinical outcomes in CUD [42, 43], effectively treating cognitive 
impairment as part of a comprehensive treatment plan for CUD could potentially improve 
important clinical outcomes, such as abstinence, quality of life, and treatment completion. 
Pharmacologic interventions are being studied to treat cognitive impairment in CUD [48-
52]. However, pharmacotherapy has limitations. Many treatment-seeking individuals with CUD 
take medications for comorbid disorders [53-55] (e.g., major depression [56], bipolar disorder 
[57], schizophrenia [58]), active cocaine use interacts with prescribed medications and other 
active drug use [59, 60], and abuse of many classes of prescribed medications is a current 
public health problem [61-64]. These limitations can lead to problems with medication 
adherence, medication-drug toxicity, and treatment dropout. Non-pharmacologic cognitive 
rehabilitation interventions can play an important role in the treatment of CUD by avoiding 
potential adverse effects from drug interactions. 
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Non-pharmacologic cognitive rehabilitation interventions have been added to substance 
use disorder treatment in those with cognitive impairment, some computerized [65-97] and 
others not [85, 98-107]. Because existing models of cognitive rehabilitation have yielded small 
to medium effect sizes in improving cognition in CUD [68, 69, 76, 77], newer models of cognitive 
rehabilitation are needed to enhance existing models and to improve cognition more effectively. 
Historically, cognitive rehabilitation has been divided into models of remediation & 
adaptation [108-111].  Remediation focuses on restoring cognition; potential mechanisms of 
restoring cognition include neuroplastic changes through prefrontal–temporal–parietal systems 
and improving brain activation in prefrontal and thalamic regions, though the mechanisms for 
remediation have not been fully elucidated [112-114]. Both non-computer-cognitive-remediation 
programs [98-107] and computer-cognitive-remediation programs [65, 66, 73-84], such as 
PSSCogRehab [67-71], NeurXercise [72], and Cogmed [75, 81, 82, 88] have been tested in 
those with SUDs (primarily in those with alcohol use disorder [AUD]). Non-computer-cognitive-
remediation programs have included repetitive paper-pencil puzzle-like tasks, cognitive tasks 
using workbooks and manuals, and card sorting tasks. Computer-cognitive-remediation 
programs have been developed by software companies across the world and have focused on 
various cognitive domains, such as working memory, attention, executive function, and problem-
solving. Only a few studies have included CUD [67-69, 76, 77]. These studies have generally 
yielded small to medium effect sizes in improving cognition in CUD (e.g., R2 = 0.08 at follow-up 
month 5 and R2 = 0.07 at follow-up month 6 [67]; Cohen’s d = 0.37 [68]; Generalized eta-
squared ηG2 = 0.069 [69]), though they may have still meaningful secondary effects, such as 
higher treatment engagement and higher treatment commitment [68]. 
Adaptation focuses on compensating for cognitive impairment. Cognitive-adaptation 
strategies include time pressure management [115] & compensatory rules [116] for attention 
deficits, memory diaries [117] & mnemonics [118] for memory deficits, and problem solving 
training [119] & goal management training [120] for executive function deficits. Various studies 
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[120-128] suggest that cognitive-adaptation can improve cognition, functional capacity, and 
subjective quality of life in various types of cognitively impaired patients, such as traumatic brain 
injury patients [129] and psychotic patients [130, 131]. A 12-visit cognitive-adaptation individual 
manual used in the study of psychotic patients [130] contained fundamental cognitive-
adaptation strategies, such as vigilance exercises, memory aids, mnemonics, rhyming, 
chunking, and problem-solving. 
There are limited data of cognitive-adaptation in those with SUDs. In 16 participants with 
psychiatric/substance use disorders and cognitive deficits [132], cognitive-adaptation strategies 
(time management, calendars, appointment books) improved punctuality for appointments. A 3-
week study in those with AUDs found younger participants to improve more on memory tests 
than older participants [133]. An 8-week study in those with AUDs found an improvement on the 
Boston Remote Memory Recognition subtest [134]. Given the literature of cognitive-adaptation 
in various populations [120-129, 131], research is warranted on the effectiveness of cognitive-
adaptation in treating cognitive impairment in CUD and whether results from other populations 
generalize to CUD. 
A strong non-pharmacologic option is to integrate concepts from the field of 
Occupational Therapy (OT) into the cognitive rehabilitation of CUD. OT improves the function of 
various cognitively impaired patients (e.g., stroke, traumatic brain injury, schizophrenia) by using 
cognitive-adaptation/compensation to enhance cognition in daily quality of life/function [120-129, 
131], and OT can address the cognitive and problem solving deficits that lead to a breakdown in 
daily life skills [135]. The effectiveness of OT-based cognitive rehabilitation in treating cognitive 
impairment in CUD has not been examined through research. A model of OT-based cognitive 
rehabilitation in CUD may strongly improve cognition, ultimately improving important clinical 
outcomes such as abstinence and quality of life. 
One neuroscience theory underlying adaptation is that adaptation may capitalize on the 
strength of habit learning to help individuals form new habits in thinking [131]. Because habit 
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learning is intact among individuals abusing substances [136, 137], OT-based cognitive 
adaptation may teach healthier habits to those with CUD that could not be achieved from 
remediation alone. Thus, we hypothesize that adding adaptation to remediation will lead to an 
improvement in clinical outcomes. This hypothesis is not tested in the present study, but rather 
could be tested in subsequent studies. As the CUD literature to date has primarily focused on 
cognitive-remediation in CUD, combining cognitive-remediation and OT-based cognitive-
adaptation represents a newer model of cognitive rehabilitation to improve cognition more 
effectively in CUD. Most prior studies use a single approach to improving cognition; this study 
will use a combined approach, hypothesizing that using two approaches to improving cognition 
could result in greater benefits than a single approach alone. 
The overall project aims were to examine the improvement in cognition, examine the 
improvement in cocaine abstinence, and examine the improvement in daily quality of 
life/function from a novel model of OT-based cognitive rehabilitation. This paper describes the 
protocol for a pilot 12-week, randomized, parallel-group outpatient study of treatment-seeking 
adults with CUD who were mild-to-moderately cognitively impaired and dissatisfied with their 
quality of life. Participants were randomized to a “Cog-Rehab” arm (drug counseling + OT-
based cognitive rehabilitation), or to a “Control” arm (drug counseling + 
psychoeducation/computer literacy). In the “Cog-Rehab” arm, OT-based cognitive rehabilitation 
consisted of adaptation strategies taught by a therapist and remediation techniques practiced on 
a computer. To control for therapist interaction and computer interaction in the “Cog-Rehab” 
arm, the “Control” arm tasks consisted of psychoeducation taught by a therapist and computer 
literacy exercises; no cognitive rehabilitation occurred in the “Control” arm. To increase 
generalizability to daily function [138-142], a part of each OT-based cognitive rehabilitation 
session occurred in various settings around the Veterans Affairs hospital where the study took 
place (e.g., cafeteria, store, coffee cart, etc.). 
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As cognitive impairment moderates clinical outcomes in CUD, effectively treating 
cognitive impairment as part of a comprehensive treatment plan for CUD could potentially 
improve important clinical outcomes. This research has the potential to improve the future 
clinical care of individuals with CUD by integrating OT-based cognitive rehabilitation as part of a 
comprehensive treatment plan for CUD. 
METHODS 
Overall Study Design 
This study was a randomized, parallel-group outpatient study of treatment-seeking 
adults with CUD. Potential participants were initially screened over the telephone. If the potential 
participant met criteria based on a telephone interview, the participant was then scheduled for 
an in-person screening visit (Figure 1.1). 
Study Setting 
 This study was conducted at the San Francisco Veterans Affairs Health Care System 
(SFVAHCS) between 7/1/2014 and 6/30/2019. The principal investigator’s office was physically 
located in the opioid treatment program (OTP) outpatient clinic at the SFVAHCS. This study was 
registered on clinicaltrials.gov (NCT01684293). This study was approved by both the University 
of California, San Francisco (UCSF) Institutional Review Board (IRB) and the SFVAHCS Clinical 
Research Workgroup. All participants were paid in cash (US dollars) for their study participation. 
Study Population 
 Word-of-mouth and flyers around the SFVAHCS were used to recruit potential 
participants for treatment-seeking adults with CUD. Because the principal investigator’s office 
was located in the OTP clinic, most participants came through word-of-mouth from the OTP 
clinic. Because flyers were also posted around the SFVAHCS, participants from outside the 
OTP clinic were eligible to participate. Sampling would be characterized as convenience, 
because one key study requirement was to be a veteran at the SFVAHCS (Table 1.1). 
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Verbal consent was used to conduct the screening telephone interview. If the potential 
participant met criteria based on the telephone interview, the individual was then scheduled for 
the first screening visit. During the first screening visit, the screening consent form for the 
screening process was reviewed by the principal investigator, any questions answered, and the 
written screening consent form was signed by the individual after the individual passed a 
screening consent quiz. The screening consent form included a Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) authorization contact form to speak with his/her primary care 
physician for collateral medical history. A waiver of consent to obtain family history, per 
45CFR46.116(c), was obtained from the IRB. For participants who passed the first and second 
screening visits, a third screening visit was scheduled. During the third screening visit, after 
reviewing all screening data, the written study consent form was signed by the participant after 
the participant passed a study consent quiz (Figure 1.1). 
 The inclusion and exclusion criteria are listed in Table 1.1. Overall, adult veterans at the 
SFVAHCS with a primary cocaine use disorder, cognitive impairment, and stable concurrent 
medical/psychiatric illnesses (if present) were targeted for recruitment. Regarding the inclusion 
criteria, based on two previous iterations of this pilot study where the study team had difficulty 
recruiting and retaining participants with active cocaine use, the decision was made to recruit 
relatively more stable participants with at least three months of remission from cocaine use. 
However, no penalty would be enforced if a participant relapsed during the study. The 1.5 
standard deviation impairment criterion on two performance-based neurocognitive measures 
was based on consensus after reviewing the literature and discussion with neuropsychologists. 
Instead of using a generic quality of life scale, the Drug User Quality of Life Scale was used to 
assess quality of life areas relevant to individuals with substance use disorders [143, 144]. 
 Regarding the exclusion criteria, because the study was conducted at the SFVAHCS, 
the presence of concurrent psychiatric and medical disorders was expected, and the study team 
aimed to recruit participants with stable concurrent disorders. The cut-off for the Beck 
 9 
 
Depression Inventory-II score [145] was chosen to exclude participants with severe depression. 
The cut-offs for the Wechsler Test of Adult Reading standard score [146] and Mini-Mental State 
Examination score [147] were chosen to exclude participants who would not be able to 
understand the reading material provided during the study due to an intellectual disability and 
severe cognitive impairment, respectively. Having an active legal issue (e.g., current charges, 
parole, or probation) was chosen as an exclusion criterion for administrative reasons to avoid 
study involvement with the court system during the study. 
Study Randomization  
Participants were randomized to the Active “Cog-Rehab” arm or the Control arm (Table 
1.2). Simple randomization was completed using the Research Randomizer website [148].  
Study Intervention 
Because the intervention in this study was a new intervention that had not been tested 
previously in a clinical setting, the IRB wanted to ensure that participants in both arms were 
receiving some form of substance use disorder treatment. As a result, weekly individual or 
group drug counseling (choice was up to each participant) was required for study participation. 
The active “Cog-Rehab” arm consisted of 36 hours of training (24 hours computer-
based, 12 hours therapist-based) over a 12-week study period (Table 1.2). The online software 
PSSCogRehab [149] was used for the 24 hours of computer-cognitive-remediation (4 modules 
[Attention, Memory, Executive, Problem Solving]). All participants came to the SFVAHCS OTP 
outpatient clinic to do the computer training, which was supervised by the principal investigator 
and research assistants. All participants progressed through the same fixed sequence of 
modules. Each module adapted to the individual's performance, and each module required 
participants to remain with a given exercise until sufficient mastery was achieved. No penalty 
would be enforced if a participant did not master all modules within 24 hours of training, and the 
participant would stop wherever they were in the sequence of modules; alternatively, we would 
not expect a participant to finish modules before 24 hours due to the sheer number of exercises 
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and increasing level of difficulty in each module. PSSCogRehab has been tested as an adjunct 
to standard of care SUD treatment in various substance use disorder [68, 69] and non-
substance use disorder populations [95, 150-157]. The 12-visit cognitive-adaptation individual 
manual by Twamley et al [130, 131] was used for the 12 hours of therapist-based training. The 
principal investigator and/or research assistants conducted the therapist trainings. Each visit 
began with teaching OT-based cognitive-adaptation strategies, and a homework assignment 
was given. Other cognitive topics such as scheduling and sleep hygiene were discussed. 
Strategies were then practiced in various settings around the SFVAHCS (e.g., cafeteria, store, 
coffee cart, pharmacy, hoptel [on-site lodging at the SFVAHCS], etc.) to link the cognitive 
strategy to a setting outside of the office and increase the generalizability to daily function; every 
1-hour visit included 45 minutes of learning in the SFVAHCS OTP outpatient clinic and 15 
minutes of practicing around the SFVAHCS. A higher dose of 24 hours for the computer-
cognitive-remediation was selected, as a stronger dose of computer-cognitive-remediation 
training may result in stronger cognitive effects [158-161]; the dose of therapist training was kept 
as 12 hours, as the cognitive-adaptation manual was designed for 12 hours of therapist-based 
training. 
The control arm also consisted of 36 hours of training (24 hours computer-based, 12 
hours therapist-based) over a 12-week study period (Table 1.2). The software Typing Master 
[162] and computer literacy topics (e.g., Microsoft Word, Excel, PowerPoint, etc.) were used for 
24 hours of computer typing exercises. All participants came to the SFVAHCS OTP outpatient 
clinic to do the computer training, which was supervised by the principal investigator and 
research assistants. Typing has been used a control arm in previous studies of cognitive 
rehabilitation for substance use disorders [67, 68]. Psychoeducation was used for the 12 hours 
of therapist-based training. The principal investigator and/or research assistants conducted the 
therapist trainings. Each visit began with teaching the psychoeducation topic, and a homework 
assignment was given. Topics were then practiced in various settings around the SFVAHCS 
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(e.g., cafeteria, store, coffee cart, pharmacy, hoptel, etc.) to link the topic to a setting outside of 
the office; every 1-hour visit included 45 minutes of learning in the SFVAHCS OTP outpatient 
clinic and 15 minutes of practicing around the SFVAHCS. Topics were selected from existing 
manuals, books, and brochures [163-167], and topics were broad yet relevant to most 
individuals with CUD. 
The number of actual study visits during the study period to complete the 36 total hours 
of training was flexible for participants in both arms to help with study attendance. However, the 
maximum number of training hours of computer-based training and/or therapist-based training 
was limited to a total of 2 hours per study visit to help prevent participant fatigue in both arms. 
Study Measurements 
After a participant was invited for a screening visit after the telephone screening 
interview (~10 minutes), initial assessments were conducted over three screening visits to 
assess each participant for study eligibility (Table 1.3). Screening visit #1 was allotted for ~2.5 
hours, screening visit #2 (neurocognitive testing) was allotted for ~3 hours, and screening visit 
#3 was allotted for ~3 hours. After obtaining the relevant written screening consent forms, each 
participant’s demographic, psychiatric, medical, substance, family, and social history was 
collected (interviewer-administered). A directly observed urine toxicology was obtained on all 
screening and subsequent study visits. A mental status examination (clinical interview by the 
principal investigator, who is a psychiatrist) was performed at each visit to screen for any 
immediate safety concerns (e.g., suicidal or homicidal ideations with intent/plan) and potentially 
exclude participants who endorsed such concerns. A physical examination and vital signs were 
only completed if none was documented in the patient’s SFVAHCS electronic medical record 
within the past 12 months. Collateral history from the medical record, primary care physician, 
and/or outpatient addiction treatment team was obtained as clinically necessary. In the third 
screening visit, the relevant written study consent forms were obtained. 
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 Assessments for psychiatric symptoms and disorders included the Mini International 
Neuropsychiatric Interview (MINI) for Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) [168] (interviewer-administered), the Beck Depression Inventory-II (BDI-II) [145] (self-
report), the State-Trait Anxiety Inventory (STAI) [169] (self-report), and screening for Attention-
Deficit Hyperactivity Disorder (ADHD) based on DSM-5 criteria [170] (interviewer-administered 
clinical interview). The MINI has similar reliability and validity properties to the Structured 
Clinical Interview Patient Edition (SCID-P) for DSM-III-R and the Composite International 
Diagnostic Interview (CIDI), but can be administered in a much shorter period of time [168, 171]. 
The BDI-II has high internal consistency, capacity to discriminate between depressed and non-
depressed participants, and good concurrent, content, and structural validity [172]. The STAI 
has very good to excellent internal consistency in a variety of samples and has good evidence 
for convergent validity by significantly correlating with other measures of anxiety, though 
discriminant validity is limited [173].  
The Timeline Followback (TLFB) Method [174, 175] (interviewer-administered) was used 
to assess route, frequency, quantity, dollar value of use, and craving severity for alcohol, 
anxiolytics, caffeine, cocaine and other stimulants (e.g., amphetamine, methamphetamine), 
hallucinogens, heroin and other opioids, inhalants, marijuana, phencyclidine, tobacco, and other 
substances (e.g., barbiturates, bath salts, steroids). The TLFB has good test-retest reliability 
[176] and validity with biological measures of substance use, such as urine tests [177, 178]. The 
Addiction Severity Index(ASI) [179] (interviewer-administered) was used to assess life domains 
relevant to individuals with substance use disorders. The ASI has good test-retest reliability 
[180-182], internal consistency, inter-rater reliability, concurrent validity [182-186], and construct 
validity [187]. The Treatment Services Review (TSR) [188] (interviewer-administered) and the 
Medication Recommendation Tracking Form (MRTF) [189] (interviewer-administered) were 
used to assess concurrent non-study-related treatments that participants were receiving. The 
TSR has adequate test-rest reliability, concurrent validity, and discriminant validity [188, 190]. 
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The MRTF has been feasible in studies of bipolar disorder [189, 191] but will need further 
reliability and validation studies in addiction populations. 
 The Cocaine Effects Questionnaire (CEQ) [192] (self-report), the Obsessive-Compulsive 
Cocaine Scale (OCCS) [193, 194] (self-report), the Cocaine Craving Questionnaire-General 
(CCQ-Gen) [195] (self-report), and the Cocaine Craving Questionnaire–Weiss (CCQ-Weiss) 
[196, 197] (self-report) were used assess the effects of cocaine and domains relevant to 
individuals with CUD. The CEQ has good construct and concurrent validity as compared with 
measures of similar constructs and cocaine use [192]. The OCCS has good internal 
consistency, test-retest reliability, predictive validity, and convergent validity [194]. The CCQ-
Gen has moderate to high reliability and good concurrent validity [195]. The CCQ-Weiss has 
high internal consistency and good predictive validity for short-term initiation of abstinence [197]. 
The University of Rhode Island Change Assessment (URICA) [198] (self-report) was used to 
assess an individual’s motivation for change. The URICA has good internal consistency [199] 
and construct validity in addiction populations, but the predictive validity is limited [200]. 
The Clinical Global Impression (CGI) Scale (Observer [CGI-O] & Self [CGI-S]) [201] was 
used to assess participants’ global functioning. However, this measure has limited reliability and 
validity in clinical samples [202]. The Sheehan Disability Scale (SDS) [203] (self-report) was 
used to assess functional disability in work/school, social life, and family life/home 
responsibilities. While the SDS has reliability and validity data in psychiatric populations such as 
mood disorders, anxiety disorders, and pathological gambling [204-206], there are no specific 
data in addiction populations. The Drug User Quality of Life Scale (DUQOL) [143, 144] 
(interviewer-administered) was used to assess quality of life areas relevant to individuals with 
substance use disorders. The DUQOL has good internal consistency, test-retest reliability, 
criterion validity, content validity, convergent validity, and discriminant validity in addiction 
populations [143, 144, 207]. The Multiple Errands Test (MET) (interviewer-administered, 
adapted to the SFVAHCS) [208-210] was used to assess real-world cognitive functional 
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performance based on tasks that participants performed around the SFVAHCS. The MET has 
no specific reliability or validity data in addiction populations. 
 Instead of relying on measures to assess one or two cognitive domains and because the 
cognitive effects of the interventions in this study have not been previously tested, a broad 
neurocognitive battery was used to assess cognition across multiple domains [211] (Table 1.4). 
The complex domains of attention, memory, executive function, and impulsivity were each 
assessed with multiple measures and modalities (self-report, interviewer-administered, paper 
and pen, computer) at screening, end of treatment, and three-month follow-up. 
The computerized Cocaine Implicit Association Test (IAT) [212-214] was used to assess 
attentional bias towards cocaine-related cues. While the IAT has been used in addiction 
populations [213, 215, 216], there are no specific reliability or validity data in such populations. 
The Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test [217] (Conditions 1, 
2, 3, and 5), the Wechsler Adult Intelligence Scale – 4th Edition (WAIS-IV) [218] Coding, and 
the WAIS-IV Symbol Search were used to assess visual attention and processing speed. The 
WAIS-IV Digit Span and the WAIS-IV Arithmetic were used to assess working memory. While 
the D-KEFS [31, 219-221] and WAIS-IV [222-224] have been used in addiction populations, 
there are no specific reliability or validity data in cocaine use disorder populations. The Hopkins 
Verbal Learning Test-Revised (HVLT-R) [225, 226] was used to assess verbal learning and 
memory. The Brief Visuospatial Memory Test-Revised (BVMT-R) [227] was used to assess 
visuospatial learning and memory. While the HVLT-R and the BVMT-R have reliability and 
validity data [228-231], there are no specific reliability or validity data in cocaine use disorder 
populations. 
 The D-KEFS and the Wisconsin Card Sorting Test (Computer Version 4) [232, 233] 
(WCST-CV4) were used to assess various types of executive function. The D-KEFS Tower Test 
was used to assess planning, rule learning, inhibition, and cognitive set. The D-KEFS Trail 
Making Test (Condition 4) was used to assess cognitive flexibility. The D-KEFS Color-Word 
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Interference Test was used to assess inhibition and switching. The WCST-CV4 was used to 
assess problem-solving, abstract reasoning, and shifting set. While the WCST-CV4 has 
reliability and validity data in various populations [234, 235], there are no specific reliability or 
validity data in cocaine use disorder populations. 
 Several measures were used to assess various types of impulsivity [236-238]. The 
Barratt Impulsiveness Scale (BIS) [239, 240] (second version, self-report) was used to assess 
motor and nonplanning attention. While the BIS has adequate reliability and validity in 
neuropsychiatric populations [241, 242] and has been used in addiction populations [242], there 
are no specific reliability or validity data in cocaine use disorder populations. The UPPS-P 
(urgency, premeditation, perseverance, sensation seeking, and positive urgency) Impulsive 
Behavior Scale [243, 244] (self-report) was used to assess urgency, sensation-seeking, 
premeditation, and perseverance. While the UPPS-P has been used in various populations 
[245, 246], there are no specific reliability or validity data in cocaine use disorder populations. 
The computerized Conners’ Continuous Performance Test (CPT) (3rd Edition) [247] was 
used to assess omissions, commissions, and perseverations. While the CPT has adequate 
reliability and validity in psychiatric populations [248, 249], there are no specific reliability or 
validity data in cocaine use disorder populations. The computerized Iowa Gambling Task (IGT) 
[250] was used to assess decision-making. The IGT has no specific reliability or validity data in 
cocaine use disorder populations [251-256]. The Monetary Choice Questionnaire (MCQ) (self-
report, PhenX Toolkit version)  [257, 258] was used to assess delayed reward discounting. The 
MCQ has no specific reliability or validity data in cocaine use disorder populations. The 
computerized Balloon Analogue Risk Task (BART) [259] was used to assess risk-taking. 
Participants were paid in cash (rounded up to the nearest dollar) for the dollar amount that they 
earned on the BART. The BART has good test-retest reliability in healthy individuals [251, 260, 
261], but there are no specific reliability or validity data in cocaine use disorder populations. 
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The Wechsler Test of Adult Reading (WTAR) [146] was used to assess premorbid 
intellectual function. While the WTAR has been good reliability and validity in other populations 
[262-264], there are no specific reliability or validity data in cocaine use disorder populations. 
The Mini-Mental State Examination (MMSE) [147] was used as a general cognitive screen. The 
MMSE has no specific reliability or validity data in cocaine use disorder populations. The WTAR 
and MMSE were only administered once during the second screening visit. 
  Additional measures were administered during the study period, end-of-
treatment, and three-month follow-up (Table 1.5). Each end-of-treatment visit and each three-
month follow-up visit was allotted for ~3 hours. The Systematic Assessment for Treatment 
Emergent Events (SAFTEE) form (interviewer-administered) [265] was used to systematically 
monitor participants for the development of any new medical or psychiatric symptoms. The 
SAFTEE has no specific reliability or validity data in cocaine use disorder populations [266-269]. 
The Credibility/Expectancy Questionnaire (CEQ) (self-report) [270] was used asses participants’ 
expectancy for improvement and credibility of the study interventions, but has no specific 
reliability or validity data in cocaine use disorder populations. The Computer System Usability 
Questionnaire (self-report) [271] was used to assess participants’ satisfaction with using the 
computerized parts of the study intervention, but has no specific reliability or validity data in 
cocaine use disorder populations. The Game Training Questionnaire (self-report) [272] was 
used to assess whether participants perceived the computer training to be effective (e.g., 
reaction time, memory, reasoning ability, etc.) and how the participants perceived the computer 
training (enjoyable, challenging, frustrating, motivated), but has no specific reliability or validity 
data in cocaine use disorder populations. A Research Study Payment Questionnaire                 
(self-report) [273-275] was created to assess on what participants used the cash that was paid 
during this study (same phrasing of categories as used in [275]), but has no specific reliability or 
validity data in cocaine use disorder populations. 
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Blinding 
 Ideally, those who assessed the primary outcomes would be blinded to the study arm. 
However, since this was a pilot study with limited funding through a career development award 
and turnover of non-permanent research assistants during the study period, outcomes were 
assessed by whichever staff was practically available to assess the outcomes at a given study 
visit. 
Adherence/Quality Assurance 
 All participants came to the SFVAHCS OTP outpatient clinic to complete all screening, 
study, end of treatment, and follow-up visit tasks. Research assistants were trained on all tasks 
and supervised by the principal investigator. Measures of adherence to the study interventions 
included the number of visits attended and the number of homework assignments completed. 
Power/Sample Size 
Because this study was a pilot trial, the initial goals were to assess feasibility of 
enrollment and acceptability of all study procedures by participants. However, a power/sample 
size calculation was still completed prior to this trial in order to help inform the conduct of a 
larger trial with cognitive, substance use, and quality of life outcomes. 
Effect sizes and confidence intervals were estimated, though there is caution regarding 
the use of pilot studies to guide power calculations for study proposals [276]. A pilot study of 40 
completers (n = 20 per arm) was deemed to be feasible and realistic with the inherent budget 
limitations of a career developmental award. With an alpha level of 0.05, 80% power, and a 1:1 
allocation ratio of Cog-Rehab arm to control arm, the minimum detectable effect size to detect 
with this sample size would be a large effect (e.g., 1 to 1.5 standard deviation change on a 
neurocognitive measure). 
 For cognitive outcomes, the literature gives some guidance on the anticipated effect 
sizes with similar cognitive outcomes as used in this study; however, the control groups used in 
these studies were not necessarily similar to that used in this study. In 14 psychotic patients, the 
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cognitive-adaptation manual used in this study had small to medium effects (Cohen’s d = 0.22 - 
0.61) on various cognitive domains [131] when combined with pharmacotherapy; the control 
group was pharmacotherapy alone. PSSCogRehab as an adjunct to standard of care long-term 
SUD residential treatment had a small effect (d = 0.37) on improving cognition in those with 
CUD and other SUDs (n = 160) [68]; the control group was an equally intensive attention control 
treatment (computer-assisted typing) similar to what is being used in this study. In primarily 
individuals with CUD (n = 27), PSSCogRehab as an adjunct to standard of care SUD treatment 
at a treatment facility had small effects (d = 0.06 - 0.29) on various cognitive domains [69]; the 
control group was similar to PSSCogRehab in all essential features, except for providing correct 
answers and module progression and compensation yoked to an individual in the active group. 
While most of these effect sizes are small to medium, we expect that because our Cog-Rehab 
arm is a combination of treatments, the effect sizes from this combination will be larger than 
what has been previously seen in the literature. 
 For substance use outcomes, drug counseling has had small to medium effects on 
decreasing drug use [277]. Because drug counseling is being used in both arms and is 
influenced by the 12-step philosophy, data from the Cocaine Collaborative Treatment Study 
show that active participation in 12-step activities had small effects on decreasing cocaine use 
(d = 0.14 - 0.47) [278]. We contacted members of the Cocaine Collaborative Treatment Study 
for guidance on estimating the effect size of drug counseling on decreasing cocaine use in 
cognitively impaired individuals with CUD. As cognitively impaired individuals with CUD may 
represent those who have CUD with a more medium/severe level of pathology from cerebral 
perfusion or metabolism anomalies [24, 47], the effect size of drug counseling on decreasing 
cocaine use in cognitively impaired individuals with CUD is highly unlikely to be medium/large 
and is more likely to be small. By potentially improving attention/memory/executive function 
deficits more effectively in the Cog-Rehab arm compared to the Control arm, we expect to 
achieve a more powerful effect on decreasing cocaine use in the Cog-Rehab arm due to 
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participants being able to better focus, attend to, remember, and think during the drug 
counseling content. 
 For quality of life outcomes, there are no prior reports of the Drug User Quality of Life 
Scale with drug counseling, the cognitive-adaptation manual, the PSSCogRehab software, or 
psychoeducation. The literature gives some guidance on the anticipated effect sizes with similar 
outcomes. In 14 psychotic patients, the cognitive-adaptation manual had medium effects (d = 
0.52 - 0.67) on total functional capacity and quality of life [131]. Thus, in this study, we would 
expect effect sizes at least this big. 
Statistical Analysis 
All data were stored in a custom-made Microsoft Access database for this study 
(Quicksilver Consulting; El Cerrito, California). The initial goals were to assess feasibility of 
enrollment and acceptability of all study procedures by participants. Feasibility of enrollment 
was assessed by tracking the number of telephone calls received, number of telephone screens 
actually completed, number of telephone callers set up for the 1st screening visit, number of 
callers who completed all screening visits in person, number of participants randomized, and 
number of participants who completed the entire study. The Computer System Usability 
Questionnaire and the Game Training Questionnaire helped assess acceptability of the study 
procedures. The distributions of variables will be examined and described as appropriate. The 
results of these analyses will be described in a second paper. 
DISCUSSION 
 This paper describes a novel protocol for a pilot 12-week, randomized, parallel-group 
outpatient study of treatment-seeking adults at the SFVAHCS with CUD who were mild-to-
moderately cognitively impaired and dissatisfied with their quality of life. Because existing 
models of cognitive rehabilitation have yielded small to medium effect sizes in improving 
cognition in CUD, newer models of cognitive rehabilitation are needed to improve cognition 
more effectively. Most prior studies use a single approach to improving cognition; this study 
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used a combined approach, hypothesizing that using two approaches to improving cognition 
could result in greater benefits than a single approach alone. 
Strengths 
First, this study adapted cognitive rehabilitation principles from the OT field to treat 
cognitive impairment in CUD. Second, OT-based cognitive-adaptation techniques were 
combined with computer-cognitive-remediation techniques to represent a newer model of 
cognitive rehabilitation in an effort to improve cognition more effectively in CUD. Third, this study 
collected a comprehensive set of psychiatric, substance use, and neurocognitive measures in 
order to demonstrate proof-of-concept of the study intervention and to gather preliminary data of 
the study intervention’s impact on different domains associated with CUD. Finally, this study 
was conducted at a VA hospital in patients with complex comorbidities in an effort to increase 
external validity to patients with CUD in other clinical settings. 
Limitations 
 This study had several limitations. First, the interventions were labor-intensive and 
required a substantial amount of training before delivery to participants, which was possible in a 
research setting. However, such a labor-intensive approach may not be easily scalable in a 
community addiction treatment setting. Second, most community-based addiction treatment 
programs will not have access to extensive neurocognitive assessments as conducted in this 
study, which limits the detailed assessment of various cognitive domains in patients treated in a 
community setting. Third, the burden on the participants was quite high, which may limit study 
participation, study completion, and ability to recruit (especially if cash incentives are not given 
in a community addiction treatment setting). 
Fourth, this study combined cognitive-adaptation techniques and cognitive-remediation 
techniques in the Cog-Rehab arm and did not determine which techniques are better or worse. 
Each set of techniques had its own contribution, and the study used a comprehensive approach 
to treat cognitive impairment. This study could not determine which active ingredient would 
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impact outcomes, though we were not planning on testing for efficacy in this study; the active 
ingredient can be teased out in future larger studies. Fifth, those who assessed the primary 
outcomes were not necessarily blinded to the study arm. Non-blinding could have biased how 
some study staff assessed participants. 
Sixth, because this study recruited individuals with at least mild cognitive impairment, the 
results from this study would not apply to those with no cognitive impairment or cognitive 
impairment not detected by classical neurocognitive measures (e.g., social cognition [279, 280], 
compulsivity [281]). Finally, study participants were required to be in at least 3 months of 
remission from their CUD diagnosis. Because this study recruited relatively stable participants 
from a substance use perspective, the results from this study may not be generalizable to those 
who are actively using cocaine or are trying to stop using cocaine. 
CONCLUSION 
CUD remains a significant public health problem in the U.S., and cognitive impairment 
moderates clinical outcomes in CUD. This first of three papers describes the protocol for a pilot 
randomized controlled trial of OT-based cognitive rehabilitation for CUD. Integrating OT-based 
cognitive rehabilitation in a comprehensive treatment plan for CUD could have a direct and 
significant positive impact on the public health burden of this population. The second paper will 
discuss recruitment numbers, feasibility and acceptability of interventions, and statistical 
analysis of collected assessments. The third and final paper will be a secondary analysis of the 
Multiple Errands Test as associated with the neurocognitive assessments. 
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Table 1.1. Inclusion and Exclusion Criteria. 
 
 
 
Inclusion Criteria 
Age 18-65 
Primary cocaine use disorder (based on DSM-5 criteria) and at least 3 months of 
remission (confirmed with urine tox) 
At least mild cognitive impairment, defined as = or > 1.5 standard deviations 
impairment on any 2 performance-based neurocognitive measures 
Needing to change quality of life, defined as self-identifying at least 2 life areas as 
needing to change on the Drug User Quality of Life Scale 
A Veteran at the San Francisco Veterans Affairs Health Care System 
Currently receiving weekly drug counseling (individual or group; at least 1 hour/week) 
through an outpatient substance use disorder treatment program 
Exclusion Criteria 
Inability to speak, read, write, and understand English 
Inadequate hearing or vision 
Concurrent substance use disorder (except tobacco or caffeine) not in at least 3 
months of remission 
A psychiatric disorder that will interfere with study participation or will make 
participation hazardous (e.g., psychosis, suicidal or homicidal ideations, severe 
anxiety) 
A depressive disorder classified as severe, defined as a Beck Depression Inventory-II 
score >29 
Current diagnosis of a bipolar disorder needing acute inpatient psychiatric 
hospitalization 
Currently symptomatic from attention-deficit/hyperactivity disorder (DSM-5 criteria) 
Any learning disorder, any type of dementia, any type of delirium, or an amnestic 
disorder due to any general medical condition 
Wechsler Test of Adult Reading standard score <70 
Mini-Mental State Examination score <24 
Current use of scheduled (i.e., prescribed) regular (i.e., daily) psychotropics or other 
medicines with a high likelihood of sedation & cognitive impairment (e.g., 
benzodiazepines, clozapine, anticholinergics) 
Currently prescribed stimulants (e.g., methylphenidate) or cognitive enhancers (e.g., 
donepezil, memantine) 
Active medical illnesses – uncontrolled diabetes, uncontrolled hypertension, 
uncontrolled thyroid dysfunction, or uncontrolled B12/folate deficiency; central 
nervous system illness with potential cognitive aspects (Parkinson’s, or Huntington’s 
dementia); Cirrhosis with complications (e.g., ascites, encephalopathy, jaundice, 
gastrointestinal bleeding); Needing acute medical hospitalization from HIV sequelae, 
such as HIV-related opportunistic infection 
Any history of any type of stroke or brain hemorrhage 
Any history of traumatic brain injury, intracranial pathology (e.g., tumor), or brain 
surgery 
Currently on probation or parole 
Concurrent participation in another study that medically/administratively interferes 
with this study 
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 Chapter 2 Abstract 
Background: Cognitive impairment is common in adults with cocaine use disorder and can 
reduce the effectiveness of treatment. Effectively treating cognitive impairment as part of a 
comprehensive treatment plan for adults with cocaine use disorder (CUD) could potentially 
improve important clinical outcomes, such as abstinence, quality of life, and treatment 
completion (e.g., cognitive-behavioral therapy, therapeutic community). Because existing 
models of cognitive rehabilitation have yielded small to medium effect sizes in improving 
cognition in CUD, newer models of cognitive rehabilitation are needed to improve cognition 
more effectively in CUD.  
Aims: Practitioners in the occupational therapy (OT) field work on improving the function of 
various cognitively impaired populations by using cognitive-adaptation techniques to enhance 
cognition in daily quality of life/function. OT can address the cognitive and problem-solving 
deficits that lead to a breakdown in daily life skills. A model of OT-based cognitive rehabilitation 
in CUD may strongly improve cognition, ultimately improving important clinical outcomes. The 
long-term goals of this research program are to examine improvement in cognition, cocaine 
abstinence, and daily quality of life/function from a novel model of OT-based cognitive 
rehabilitation. This randomized pilot trial was needed to address potential areas of uncertainty 
before conducting a future larger definitive randomized controlled trial (RCT). 
Methods: This paper describes the feasibility, acceptability, and preliminary effect sizes for a 
pilot 12-week, randomized, parallel group outpatient study of 31 treatment-seeking adults (age 
18-65) with CUD (with 3 or more months of remission) who were mild-to-moderately cognitively 
impaired and dissatisfied with their quality of life. Participants were randomized to a Cog-Rehab 
arm (drug counseling + OT-based cognitive rehabilitation), or to a Control arm (drug counseling 
+ psychoeducation/computer exercises). Acceptability of study procedures was assessed at the 
end of treatment with the Computer System Usability Questionnaire [range from 1 (strongly 
agree) to 7 (strongly disagree)] and the Game Training Questionnaire. Urine toxicology at each 
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visit tested for cocaine, marijuana, opiates, methamphetamines, amphetamine, phencyclidine, 
benzodiazepines, and barbiturates. Attention, memory, executive function, and impulsivity 
neurocognitive assessments were conducted at baseline, end of treatment (12 weeks), and 
follow-up (24 weeks). For each measure, an effect size was calculated by subtracting mean 
change in Cog-Rehab Arm from mean change in Control Arm and dividing by the pooled 
standard deviation. A positive sign for a between-group effect size for neurocognitive 
assessments means favoring the Cog-Rehab arm, and a negative sign for an effect size means 
favoring the Control arm. 
Results: 100% of enrolled study participants completed all study procedures (16 Cog-Rehab 
arm, 15 Control arm). Study participants had a mean age of 57.5 years (SD 5.8), 30 (96.8%) 
were male, 19 (61.3%) were Black, 12 (38.7%) were White, 6 (19.4%) were Latino, 15 (48.4%) 
were single, and had a mean education of 12.8 years (SD 1.4). Participants in both groups were 
similar in sex, age, education, race, ethnicity, marital status, retirement status, and handedness. 
Based on the Computer System Usability Questionnaire, participants in the Cog-Rehab and 
Control arms had similar ratings on the mean overall satisfaction score (1.9 vs. 2.0, P = 0.90). 
Based on the Game Training Questionnaire, participants in the Cog-Rehab and Control arms 
had similar ratings for whether they perceived the computer training to be enjoyable (81.3% vs. 
60%, Fisher’s exact p = 0.19). Participants in the Cog-Rehab arm completed a significantly 
greater percentage of homework assignments (65.3%) than those in the Control arm (32.7%) 
[Χ2(2) = 36.2; P < 0.0001]. There were no significant differences between groups in relapse to 
any substance at any timepoint. Most of the between-group effect sizes for neurocognitive 
measures and functional assessments had 95% confidence intervals that crossed zero. Some 
significant between-group effect sizes were found for certain neurocognitive measures (favoring 
Cog-Rehab arm: attentional bias 1.0, attention 0.7, visual memory 0.8, executive function 1.0) 
and one functional assessment (favoring Cog-Rehab arm: Drug User Quality of Life Score 0.8). 
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Discussion: This study found that a novel OT-based approach for improving cognition in adults 
with CUD and cognitive impairment is feasible and acceptable and provides preliminary 
evidence for efficacy based on effect sizes. CUD remains a significant public health problem in 
the U.S., and effectively treating cognitive impairment as part of a comprehensive treatment 
plan for CUD could potentially improve important clinical outcomes. Based on this pilot trial’s 
feasibility, acceptability, and preliminary effect sizes, we believe a definitive RCT is warranted. 
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Chapter 2 Main Body 
INTRODUCTION 
Cocaine use disorders (CUDs) remain a significant U.S. public health problem [282, 
283]. Relapse to cocaine use among those with a CUD is common [284, 285], with data 
showing that less than 25% of those with CUD remain abstinent over a 1-year period after 
participating in outpatient empirically-based behavioral (individual or group) and pharmacologic 
therapies [286]. Cognitive impairment in those with substance use disorders (SUDs) [287-291] 
is associated with relapse [292, 293], lower likelihood of treatment completion (e.g., cognitive-
behavioral therapy, therapeutic community) [294-298], lower motivation [299], and worse quality 
of life [300, 301]. Effectively treating cognitive impairment as part of a comprehensive treatment 
plan for CUD could potentially improve important clinical outcomes, such as abstinence, quality 
of life, and treatment completion. Because existing models of cognitive rehabilitation have 
yielded small to medium effect sizes in improving cognition in CUD [302-305] (e.g., working 
memory training, combination of working memory training and medication), newer models of 
cognitive rehabilitation are needed to enhance existing models and to improve cognition more 
effectively.  
One field where practitioners work on improving the function of various cognitively 
impaired patients (e.g., stroke, traumatic brain injury, schizophrenia) by using cognitive-
adaptation/compensation to enhance cognition in daily quality of life/function [306-316] is 
occupational therapy (OT). OT can address the cognitive and problem solving deficits that lead 
to a breakdown in daily life skills [317]. A model of OT-based cognitive rehabilitation in CUD 
may strongly improve cognition, ultimately improving important clinical outcomes.  
The effectiveness of OT-based cognitive rehabilitation in treating cognitive impairment in 
CUD has not been examined through research. This study was a pilot 12-week, randomized, 
parallel-group outpatient study of treatment-seeking (for cognitive difficulties) adults (age 18-65) 
with CUD (with 3 or months of remission) who were mild-to-moderately cognitively impaired and 
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dissatisfied with their quality of life. Participants were randomized to a Cog-Rehab arm (drug 
counseling + OT-based cognitive rehabilitation), or to a Control arm (drug counseling + 
psychoeducation/computer literacy).  
 This randomized pilot trial was needed to address potential areas of uncertainty before 
conducting a future larger definitive randomized controlled trial. Areas of uncertainty included 
feasibility of recruiting adults with CUD with 3 or months of remission, feasibility of randomizing 
participants who met strict eligibility criteria, feasibility and acceptability of completing a lengthy 
neurocognitive battery at three timepoints, feasibility and acceptability of completing the 
complex interventions in the Cog-Rehab and Control arms, feasibility of completing homework 
assignments during the study period, and feasibility and acceptability of attending lengthy study 
visits at three timepoints. Observing how these areas of uncertainty unfolded in this pilot trial 
helped determine the feasibility of conducting a larger future definite randomized controlled trial. 
The overall project aims were to examine the improvement in cognition, examine the 
improvement in cocaine abstinence, and examine the improvement in daily quality of 
life/function from a novel model of OT-based cognitive rehabilitation. The first of three papers 
described the protocol for the pilot study. This second paper will discuss recruitment, feasibility 
and acceptability of assessments and interventions, and estimate effect sizes for clinical 
outcomes. The CONSORT extension to randomized pilot and feasibility trials was used as a 
guide for this second paper [318]. The third and final paper will be a secondary analysis of the 
Multiple Errands Test as associated with the neurocognitive assessments. 
METHODS 
Overall Study Design 
This study was a randomized, parallel-group outpatient study of adults with CUD who 
had 3 months of self-reported remission from cocaine use and were seeking treatment for 
cognitive difficulties. If a potential participant met criteria based on a telephone interview, the 
participant was then scheduled for an in-person screening visit. The study protocol can be 
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accessed by contacting the principal investigator. No changes were made to this protocol after 
the trial started. 
Study Setting 
This study was conducted at the San Francisco Veterans Affairs Health Care System 
(SFVAHCS) between 7/1/2014 and 6/30/2019. This study was registered on clinicaltrials.gov 
(NCT01684293). This study was approved by both the University of California, San Francisco 
(UCSF) Institutional Review Board (IRB) and the SFVAHCS Clinical Research Workgroup. All 
participants were paid in cash (US dollars) for their study participation. The funding source 
(National Institute on Drug Abuse) had no role in the design of this study and had no role during 
its execution, analyses, interpretation of the data, or decision to submit results. 
Study Recruitment 
Word-of-mouth and flyers around the SFVAHCS were used to recruit potential 
participants for treatment-seeking adults with CUD. Because the principal investigator’s office 
was located in the opioid treatment program (OTP) clinic, most participants came through word-
of-mouth from the OTP clinic. 
Verbal consent was used to conduct the screening telephone interview. If the potential 
participant met criteria based on the telephone interview, the individual was then scheduled for 
the first screening visit. During the first screening visit, the screening consent form for the 
screening process was reviewed by the principal investigator, any questions answered, and the 
written screening consent form was signed by the individual after the individual passed a first 
screening consent quiz. For participants who passed the first and second screening visits, a 
third screening visit was scheduled. Neurocognitive testing occurred during the second 
screening visit. During the third screening visit, after reviewing all screening data (inclusion and 
exclusion criteria list in chapter #1), the written study consent form was signed by the participant 
after the participant passed a second study consent quiz. The Multiple Errands Test was also 
administered at the third screening visit. 
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Study Randomization  
Participants were randomized in a 1:1 allocation ratio to the Cog-Rehab arm or the 
Control arm. Simple randomization with no restriction or blocking was completed using the 
Research Randomizer website [319]. No steps were taken to conceal the sequence. The 
principal investigator generated the random allocation sequence, enrolled and consented 
participants, and assigned participants to interventions. 
Study Intervention 
Because the intervention in this study was a new intervention that had not been tested 
previously in a clinical setting, the IRB and the research team wanted to ensure that participants 
in both arms were receiving some form of substance use disorder treatment. As a result, weekly 
individual or group drug counseling (choice was up to each participant) was required for study 
participation. 
In the Cog-Rehab arm, OT-based cognitive rehabilitation consisted of adaptation 
strategies taught by a therapist (Bachelors level research assistant) and remediation techniques 
practiced on a computer. The active Cog-Rehab arm consisted of 36 hours of training (24 hours 
computer-based, 12 hours therapist-based) over a 12-week study period. The online software 
PSSCogRehab [320] was used for the 24 hours of computer-cognitive-remediation (4 modules 
[Attention, Memory, Executive, and Problem Solving]). The 12-visit cognitive-adaptation 
individual manual by Twamley et al [308, 321] was used for the 12 hours of therapist-based 
training. A homework assignment was given for 11 out of the 12 therapist-based training visits; 
each assignment helped reinforce the content discussed in the therapist-based training visit. 
To control for therapist interaction and computer interaction in the Cog-Rehab arm, the 
Control arm tasks consisted of psychoeducation taught by a therapist (Bachelors level research 
assistant) and computer literacy exercises; no cognitive rehabilitation occurred in the Control 
arm. The Control arm also consisted of 36 hours of training (24 hours computer-based, 12 hours 
therapist-based) over a 12-week study period. The software Typing Master [322] and computer 
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literacy topics (e.g., Microsoft Word, Excel, PowerPoint, etc.) were used for 24 hours of 
computer typing exercises. Psychoeducation focusing on general behavioral health topics was 
used for the 12 hours of therapist-based training; no specific manual was used, but a list of 
topics was compiled for the purpose of this study. A homework assignment was given for 11 out 
of the 12 therapist-based training visits; each assignment helped reinforce the content 
discussed in the therapist-based training visit. 
To increase generalizability to daily function [323-327], a part of each session in both 
arms occurred in various settings around the Veterans Affairs hospital where the study took 
place (e.g., cafeteria, store, coffee cart, etc.). Further details on the intervention were described 
in the first paper. 
Study Measurements 
 Feasibility data were collected throughout the enrollment, intervention, and follow-up 
periods. Feasibility measures included: a) ability to recruit adults with CUD with 3 or months of 
remission, b) ability to randomize participants who met strict eligibility criteria, c) ability to 
complete a lengthy neurocognitive battery at three timepoints, d) ability to complete the complex 
interventions in the Cog-Rehab and Control arms, e) ability to complete eleven homework 
assignments during the study period, and f) ability to complete outcome assessments at three 
timepoints. 
Metrics of tracking feasibility included the number of telephone calls received, number of 
telephone screens actually completed, number of telephone callers set up for the 1st screening 
visit, number of callers who completed all screening visits in person, number of participants 
randomized, number of participants who completed the entire study, number of total study visits 
attended, and percent of homework assignments completed during the study period (out of 
eleven homework assignments). 
Acceptability of study procedures was assessed at the end of treatment with the 
Computer System Usability Questionnaire and the Game Training Questionnaire. The 19-item 
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self-report Computer System Usability Questionnaire (CSUQ) [328] was used to assess 
participants’ satisfaction with using the computerized parts of the study intervention; each item 
had seven answer choices, ranging from 1 (strongly agree) to 7 (strongly disagree), and four 
scores were calculated (overall satisfaction, system usefulness, information quality, interface 
quality). The self-report Game Training Questionnaire (GTQ) [329] assessed how the 
participants perceived the computer training (4-item Part 2 – enjoyable, challenging, frustrating, 
motivated); each question had seven answer choices, ranging from very strongly disagree to 
very strongly agree. 
Outcome measures for a future definitive randomized controlled trial were included in 
this pilot trial to assess the feasibility of research staff administering these measures and the 
feasibility of participants completing these measures and to provide proof-of-concept by 
estimating effect sizes. Sociodemographics were collected at baseline by self-report via a 
structured interview. Clinical characteristics were collected at baseline by various methods, such 
as self-report and the interviewer-administered Mini International Neuropsychiatric Interview 
(MINI) for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [330]. Urine 
toxicologies were conducted at baseline, during the treatment period, end of treatment, and 
follow-up. Urine toxicology at each visit tested for cocaine, marijuana, opiates, 
methamphetamines, amphetamine, phencyclidine, benzodiazepines, and barbiturates using the 
rapid one-step Alere iScreen drugs of abuse screening test card (Alere; Portsmouth, Virginia). 
    The Wechsler Test of Adult Reading (WTAR) [331] was used to assess premorbid 
intellectual function. The Mini-Mental State Examination (MMSE) [332] was used as a general 
cognitive screen. The WTAR and MMSE were only administered once at baseline. 
Attention neurocognitive assessments at baseline, end of treatment, and follow-up 
included the Cocaine Implicit Association Test (Cocaine IAT), Delis–Kaplan Executive Function 
System (D-KEFS) Trail Making Test (Number Sequencing subtest), and Wechsler Adult 
Intelligence Scale Fourth Edition (WAIS-IV) Processing Speed Composite (Coding and Symbol 
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Search). The computerized Cocaine Implicit Association Test (IAT) [333-336] was used to 
assess attentional bias towards cocaine-related cues. The GNB (Greenwald, Nosek, and 
Banaji) score for the IAT is approximately similar to an effect size measure (such as Cohen’s d; 
full details described elsewhere [335, 336]). Positive values reflected positive valence towards a 
concept (towards cocaine in this study), and negative values reflected negative valence away 
from a concept (away from cocaine in this study). For the D-KEFS [337], scaled scores were 
used for the Trail Making Test Number Sequencing subtest. The WAIS-IV [338] Processing 
Speed Composite Score was interpreted as an intelligence quotient standard score (mean = 
100; standard deviation = 15; lower score means worse performance). 
Memory neurocognitive assessments at baseline, end of treatment, and follow-up 
included the WAIS-IV Working Memory Composite (Digit Span and Arithmetic), Hopkins Verbal 
Learning Test-Revised (HVLT-R), and Brief Visuospatial Memory Test-Revised (BVMT-R). The 
WAIS-IV [338] Working Memory Composite Score was interpreted as an intelligence quotient 
standard score (mean = 100; standard deviation = 15; lower score means worse performance). 
For the HVLT-R [339, 340] and BVMT-R [341], T-scores (mean = 50; standard deviation = 10; 
lower score means worse performance) were used for all scores. 
Executive function neurocognitive assessments at baseline, end of treatment, and 
follow-up included the D-KEFS Trail Making Test (Number-Letter Switching subtest) and 
Wisconsin Card Sorting Test (Computer Version 4) [WCST]. Scaled scores were used for the D-
KEFS Trails Number-Letter Switching subtest. T-scores were used for the computerized WCST 
[342, 343] Total Errors score.  
Impulsivity neurocognitive assessments at baseline, end of treatment, and follow-up 
included the Barratt Impulsiveness Scale (BIS), UPPS-P (urgency, premeditation, 
perseverance, sensation seeking, positive urgency) Impulsive Behavior Scale, and Iowa 
Gambling Task (IGT). For the 30-item self-report BIS [344, 345], each item had four answer 
choices (1 to 4), and the total score was calculated. For the 50-item self-report UPPS-P [346, 
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347], each item had four answer choices (1 [agree strongly] to 4 [disagree strongly]), and a 
Sensation seeking score was calculated. For the computerized IGT [348], T-scores were used 
for all scores. 
 Quality of life and functional assessments at baseline, end of treatment, and follow-up 
included the Drug User Quality of Life Scale (DUQOL) and Multiple Errands Test (MET). For the 
22-item DUQOL [349, 350], each item had seven answer choices (1 [very dissatisfied] to 7 [very 
satisfied]). A total score was calculated from the 22 items. Regarding the MET [351-353], a 
performance efficiency score was calculated (total tasks completed / total locations visited), and 
a normalized performance efficiency score was calculated (performance efficiency score / 1.625 
[the ideal performance efficiency score, based on 13 tasks / 8 locations = 1.625]). 
No changes were made to the measures after this pilot trial commenced. Criteria to 
judge whether to proceed with a future definitive randomized controlled trial included achieving 
the six feasibility measures specified above. No interim analyses of measures were planned.  
Stopping guidelines for the entire study were not considered at study inception. 
However, all adverse events reported by a participant or observed by research staff would have 
been individually listed on an Adverse Event Form. Should any serious and/or unexpected 
adverse events have occurred, procedures were in place to notify (within 24 hours) the IRB, 
State of California Committee for the Protection of Human Subjects, Quality Improvement Unit 
at the IRB, the NIDA Project Officer, and the Data Safety Monitoring Board (consisted of three 
psychiatrists at the SFVAHC who were not affiliated with this study). Relevant data and any 
available follow-up reports would have been reported to the Project Officer and to NIDA via the 
Serious Adverse Event Tracking and Reporting System. The entire team would have 
determined whether the seriousness of the event warranted removal of the participant from the 
study. 
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Blinding 
 Ideally, those who assessed the primary outcomes would be blinded to the study arm. 
However, since this was a pilot study with limited funding through a career development award 
and turnover of non-permanent research assistants during the study period, outcomes were 
assessed by whichever staff was practically available to assess the outcomes at a given study 
visit; some staff were aware of the study arm assignments. Participants were aware of which 
intervention they received. 
Adherence/Quality Assurance 
 All participants came to the SFVAHCS OTP outpatient clinic to complete all screening, 
study, end of treatment, and follow-up visit tasks. Research assistants were trained on all tasks 
and supervised by the principal investigator; participants’ charts were audited periodically for 
data integrity by the principal investigator and the SFVAHCS research compliance officer. 
Adherence to the study interventions by study staff was assessed with study session checklists. 
Statistical Analysis 
All data for each participant were first stored in a dedicated study binder for each 
participant. Data were then entered into a custom-made Microsoft Access database for this 
study (Quicksilver Consulting; El Cerrito, California) by research assistants. Data from this 
Microsoft Access database were then converted to Stata files using Stat/Transfer version 14 for 
Windows (Circle Systems, Inc.; Seattle, Washington.) All analyses were finally conducted using 
Stata/SE 16.1 for Windows (5/20/2020 revision; StataCorp, LLC; College Station, Texas). 
The distributions of variables were examined and described as appropriate with 
descriptive statistics (e.g., mean, standard deviation, percentage). Baseline sociodemographics 
and clinical characteristics of the Cog-Rehab Arm and the Control Arm were compared using t-
tests for continuous variables and chi-square or Fisher’s exact tests for categorical variables. 
These techniques also were used to compare feasibility and acceptability measures between 
groups. For each measure, an effect size was calculated by subtracting mean change in Cog-
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Rehab Arm from mean change in Control Arm and dividing by the pooled standard deviation. 
Three between-group effect sizes were calculated for each measure: a) end of treatment 
change from baseline, b) follow-up change from baseline, and c) follow-up change from end of 
treatment. Effect sizes generally >=0.2 are considered small, >=0.5 are considered medium, 
and >=0.8 are considered large [354]. A positive sign for an effect size means favoring the Cog-
Rehab arm, and a negative sign for an effect size means favoring the Control arm. 
RESULTS 
Description of Study Participants 
Out of 143 telephone calls received (Figure 2.1), eighty-five screening phone calls were 
completed. Fifty-eight potential callers did not call back, despite research staff returning their 
phone call. Out of those 85 phone calls, 12 callers declined to participate, 38 callers were 
initially ineligible over the phone, and 36 callers were scheduled for an in-person screening visit. 
Four callers did not show up for the first screening visit and were also deemed ineligible, 
bringing the total ineligible callers to 42. Thirty-two callers were screened in person, one of 
whom was severely depressed and excluded at the first in-person screening visit. Thirty-one 
participants were randomized in the study. 
Reasons for declining to participate (Figure 2.1) included living too far away, being too 
busy to participate, and not interested in the study. Reasons for ineligibility (Figure 2.1) included 
having a high suicide risk flag in the medical record, severe depression, having an active 
serious medical issue, taking an exclusionary medication, not showing up for the first screening 
visit, not being a cocaine user, having active legal issues, still using cocaine or another illicit 
drug, being over the age of 65, and being banned from the clinic for assaultive behavior. Sixteen 
participants completed the Cog-Rehab arm, and fifteen participants completed the Control arm. 
Overall, study participants had a mean age of 57.5 years (SD 5.8), 30 (96.8%) were 
male, 19 (61.3%) were Black, 12 (38.7%) were White, 6 (19.4%) were Latino, 15 (48.4%) were 
single, and had a mean education of 12.8 years (SD 1.4). Participants in both groups (Table 
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2.1) were similar in sex, age, education, race, ethnicity, marital status, retirement status, and 
handedness. Control arm participants were significantly older when they became regular 
cocaine users (age 29) than Cog-Rehab arm participants (age 23) [t(29) = -2.2; -11.4 to -0.5; P 
= 0.03]. Participants in both groups had similar psychiatric diagnoses. 
Feasibility and Acceptability Assessments and Urine Toxicology Assessments 
Metrics of tracking feasibility included the number of telephone calls received (143 calls), 
number of telephone screens actually completed (85 screened), number of telephone callers set 
up for the 1st screening visit (36 callers), number of callers who completed all screening visits in 
person (31 callers), number of participants randomized (31 participants), number of participants 
who completed the entire study (31 participants: 16 Cog-Rehab arm, 15 Control arm), and 
number of total study visits attended (participants in both arms attended all study visits). 
Participants in the Cog-Rehab arm completed a significantly greater percentage of homework 
assignments (65.3%) than those in the Control arm (32.7%) [Χ2(2) = 36.2; P < 0.0001]. 
 Acceptability of study procedures was assessed at the end of treatment with the 
Computer System Usability Questionnaire and the Game Training Questionnaire (Table 2.2). 
Based on the Computer System Usability Questionnaire, participants in the Cog-Rehab and 
Control arms had similar ratings [range from 1 (strongly agree) to 7 (strongly disagree)] on the 
mean overall satisfaction score (1.9 vs. 2.0, P = 0.90), mean system usefulness score (2.0 vs. 
2.1, P = 0.84), mean information quality score (2.0 vs. 2.0, P = 1.0), and mean interface quality 
score (1.9 vs. 2.0, P = 0.88). Based on the Game Training Questionnaire, participants in the 
Cog-Rehab and Control arms had similar ratings for whether they perceived the computer 
training to be enjoyable (81.3% vs. 60%, Fisher’s exact p = 0.19), challenging (56.3% vs. 
66.7%, Fisher’s exact p = 0.40), frustrated (31.3% vs. 13.3%, Fisher’s exact p = 0.20), and 
motivated (62.5% vs. 60%, Fisher’s exact p = 0.06). 
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There were no significant differences between the number of participants in both arms 
that relapsed to any substance during the treatment period, end of treatment, and follow-up 
(Table 2.3). 
Neurocognitive Measures and Functional Assessments 
Research staff were able to administer all measures to participants. Participants were 
able to complete a lengthy neurocognitive battery at three timepoints. Overall, study participants 
had a mean WTAR score of 95.2 (SD 13.7) and a mean MMSE score of 28.1 (SD 1.3). 
Participants in both groups did not differ significantly on these measures. 
For the change from baseline to end of treatment effect sizes (Tables 2.4 and 2.5), most 
of the between-group effect sizes had 95% confidence intervals that crossed zero. A significant 
medium effect size was observed for the BVMT-R Total Recall T-score (0.8, favoring the Cog-
Rehab arm). While some measures had effect sizes that appeared to favor the Cog-Rehab arm 
(e.g., Cocaine Implicit Association Test, D-KEFS Trails Number-Letter Switching, Wisconsin 
Card Sorting Test, UPPS-P Sensation seeking, Barratt Impulsiveness Scale, Drug User Quality 
of Life Scale, Multiple Errands Test), the 95% confidence intervals crossed zero for these effect 
sizes. 
For the change from end of treatment to follow-up effect sizes (Tables 2.4 and 2.5), most 
of the between-group effect sizes had 95% confidence intervals that crossed zero. A significant 
large effect size was observed for the Cocaine Implicit Association Test GNB score (1.0, 
favoring the Cog-Rehab arm), even though there was no significant between-group effect size 
from baseline to end of treatment for this measure. A significant medium effect size was 
observed for the D-KEFS Trails Number Sequencing scaled score (0.7, favoring the Cog-Rehab 
arm), even though there was no significant between-group effect size from baseline to end of 
treatment for this measure. While some measures had effect sizes that appeared to favor the 
Cog-Rehab arm (e.g., WAIS-IV Processing Speed, WAIS-IV Working Memory, HVLT-R,) or the 
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Control arm (e.g., Barratt Impulsiveness Scale, Multiple Errands Test), the 95% confidence 
intervals crossed zero for these effect sizes. 
Most of the change from baseline to follow-up between-group effect sizes (Tables 2.4 
and 2.5) for the between-group effect sizes had 95% confidence intervals that crossed zero. For 
the between-group effect size for the BVMT-R Total Recall T-score, the effect was maintained 
from baseline to follow-up (significant large effect size 0.8, favoring the Cog-Rehab arm). A 
significant large effect size was observed for the Wisconsin Card Sorting Test Total Errors T-
score (1.0, favoring the Cog-Rehab arm), even though there were no significant between-group 
effect sizes from baseline to end of treatment or from end of treatment to follow-up for this 
measure. A significant medium effect size was observed for the Drug User Quality of Life Scale 
total score (0.8, favoring the Cog-Rehab arm), even though there were no significant between-
group effect sizes from baseline to end of treatment or from end of treatment to follow-up for this 
measure. While some measures had effect sizes that appeared to favor the Cog-Rehab arm 
(e.g., HVLT-R, UPPS-P Sensation seeking) or the Control arm (e.g., Cocaine Association 
Implicit Test, Iowa Gambling Task), the 95% confidence intervals crossed zero for these effect 
sizes. 
DISCUSSION 
100% of enrolled study participants completed all study procedures (16 Cog-Rehab arm, 
15 Control arm). Regarding feasibility measures: a) we were able to recruit adults with CUD with 
3 or months of remission, b) we were able to randomize participants who met strict eligibility 
criteria, c) participants were able to complete a lengthy neurocognitive battery at three 
timepoints, d) participants were able to complete the complex interventions in the Cog-Rehab 
and Control arms, e) not all participants were able to complete eleven homework assignments 
during the study period, and f) participants were able to complete outcome assessments at 
three timepoints. Research staff were able to administer all measures to participants. 
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Though all participants attended all study visits, participants in the Cog-Rehab arm 
completed a significantly greater percentage of homework assignments than those in the 
Control arm. At the end of treatment, participants in both arms had similar high (strongly agree) 
usability and acceptability ratings for study procedures and had similar ratings for how they 
perceived the computer training (highly enjoyable, moderately challenging, low frustration, 
moderately motivated).  
While we were hoping to see improvements on all neurocognitive measures and 
functional assessments since the cognitive rehabilitation content targeted all domains, most of 
the between-group effect sizes for neurocognitive measures and functional assessments had 
95% confidence intervals that crossed zero. Some significant between-group effect sizes were 
found; however, given the sheer number of neurocognitive measures administered and a small 
study sample size, one explanation for these significant findings is chance. 
A significant medium effect size that favored the Cog-Rehab arm was observed for the 
BVMT-R Total Recall from baseline to the end of treatment, and a significant large effect size 
that favored the Cog-Rehab arm was observed for the BVMT-R Total Recall from baseline to 
follow-up. Aside from chance, perhaps the Cog-Rehab intervention had a true effect on a 
measure of visual memory since visual memory training was a component of the intervention. A 
significant medium effect size that favored the Cog-Rehab arm was observed for the D-KEFS 
Trails Number Sequencing from end of treatment to follow-up. Aside from chance, an 
explanation for this finding is not apparent at this time and will need to be explored in a future 
definitive RCT. 
A significant large effect size that favored the Cog-Rehab arm was observed for the 
Cocaine Implicit Association Test GNB score from end of treatment to follow-up. The lower the 
GNB score, the greater the level of attentional bias away from cocaine. Cog-Rehab arm 
participants decreased in their mean GNB score (attentional bias away from cocaine), and 
Control arm participants increased in their mean GNB score (attentional bias towards cocaine). 
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Since Cog-Rehab arm participants were taught skills to help their cognitive impairment 
(whereas Control arm participants were not taught such skills), perhaps Cog-Rehab arm 
participants began to realize the deleterious effects of cocaine and started to become biased 
away from cocaine-related cues. This preliminary explanation will need further exploration in a 
future definitive RCT. 
A significant large effect size that favored the Cog-Rehab arm was observed for the 
Wisconsin Card Sorting Test Total Errors from baseline to follow-up. A significant medium effect 
size that favored the Cog-Rehab arm was observed for the Drug User Quality of Life Scale total 
score from baseline to follow-up. Aside from chance, these significant effect sizes were perhaps 
related to Control arm participants worsening over time due to not receiving an intervention to 
target their cognitive impairment. Also, the effect sizes for both of these measures from baseline 
to end of treatment were in the same direction, even though they were not significant. 
Another explanation for some of the significant effect sizes for neurocognitive measures 
is participants could have “trained to the task” [355]. For example, the computer exercises 
contain exercises that are similar to the Wisconsin Card Sorting Test. Visual exercises are 
integrated into the therapist training, and thus may explain the significant results on the BVMT-
R. The future definitive RCT must be careful to not include outcome measures that are too 
similar to the cognitive training being delivered to participants.  
Though the intervention was complex and there were many assessments, participants 
completed all assessments. In this study, participants were assessed comprehensively with 
various assessments – feasibility, acceptability, psychiatric, clinical, neurocognitive, quality of 
life, function – which we felt was important to understand participants fully, rather than focus 
only on one or two aspects of their lives. Even though some measures showed medium to large 
effect sizes that favored the Cog-Rehab participants, most quality of life and functional 
assessments showed similarity in both groups across timepoints. Only using neurocognitive 
measures in this study would have given an impression that participants’ cognition meaningfully 
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improved. Other than the one significant medium effect size that favored the Cog-Rehab arm for 
the Drug User Quality of Life Scale (which could have been due to chance), having 
complementary quality of life and functional assessments showed that improvements on 
neurocognitive measures didn’t necessarily transfer into real-world functional improvements. 
 This difficulty in transfer to real-world functional improvements has also been observed 
in other populations, such as persons with traumatic brain injury [356, 357], schizophrenia [358], 
and older adults [359]. Techniques that are being used concurrently with cognitive training in 
these other populations to help with transfer to functional improvements include vocational 
rehabilitation, self-awareness training, virtual reality training, videoconferencing, and social skills 
training. Adding such techniques to cognitive training for persons with substance use disorder 
can be explored in a future definitive RCT. 
 Strengths 
First, we collected a comprehensive set of psychiatric, substance use, and 
neurocognitive measures in order to demonstrate proof-of-concept of the study intervention and 
to gather preliminary data of the study intervention’s impact on different domains associated 
with CUD. Second, we conducted this study at a veteran’s hospital in patients with complex 
comorbidities in an effort to maximize internal validity for this little-studied population. 
Third, the interventions in this study were relatively low technology to implement by 
research staff with a college degree. The interventions were feasible and acceptable to 
participants, as participants attended study visits and none dropped out. Finally, quality of life 
and functional assessments helped complement the neurocognitive assessments in assessing 
the overall impact of the intervention. 
Limitations 
 This study had several limitations. First, though the interventions were low technology, 
the interventions were still labor-intensive and required a substantial amount of training before 
delivery to participants. Such a labor-intensive approach may not be easily scalable in a 
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community addiction treatment setting. If this intervention proved to be efficacious in a future 
definitive RCT, it would likely need to be effective on a larger scale. Second, though participants 
completed all of their study visits, this was likely due to being paid in cash for each study visit. 
Adherence may not be as high for patients in an outpatient clinical setting without such external 
cash incentives. 
Third, this study combined cognitive-adaptation techniques and cognitive-remediation 
techniques in the Cog-Rehab arm and did not determine which techniques were better or worse. 
Each set of techniques had its own contribution, and the study used a comprehensive approach 
to treat cognitive impairment. This study could not determine which active ingredient would 
impact outcomes, though we were not planning on testing for efficacy in this study; the active 
ingredient can be teased out in a future definitive RCT. Fourth, study staff were aware of the 
randomization sequence, and those who assessed the primary outcomes were not necessarily 
blinded to the study arm. Non-blinding could have biased how some study staff assessed 
participants. These limitations can be addressed in a future definitive RCT. 
Fifth, because this study recruited individuals with at least mild cognitive impairment, the 
results from this study may not generalize to those with no cognitive impairment or cognitive 
impairment not detected by classical neurocognitive measures (e.g., social cognition [360, 361], 
compulsivity [362]). Sixth, the homework assignments in the Control arm were either likely 
difficult to complete or not engaging enough to complete. The content of the homework 
assignments would need to be revisited before conducting a future definitive RCT. Finally, study 
participants were required to be in at least 3 months of remission from their CUD diagnosis. 
Because this study recruited relatively stable participants from a substance use perspective, the 
results from this study may not generalize to those who are actively using cocaine or are trying 
to stop using cocaine. 
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CONCLUSIONS 
CUD remains a significant public health problem in the U.S., and effectively treating 
cognitive impairment as part of a comprehensive treatment plan for CUD could potentially 
improve important clinical outcomes. The first of three papers described the protocol for a pilot 
randomized controlled trial of OT-based cognitive rehabilitation for CUD. Integrating OT-based 
cognitive rehabilitation in a comprehensive treatment plan for CUD could have a direct and 
significant positive impact on the public health burden of this population.  
This second paper shows the feasibility, acceptability, and preliminary effect sizes of an 
OT-based intervention to improve cognitive function in patients with CUD. Participants in both 
arms had similar high usability and acceptability ratings for study procedures and had similar 
ratings for how they perceived the computer training. Participants in the Cog-Rehab arm 
completed a significantly greater percentage of homework assignments than those in the 
Control arm. At follow-up, there were no significant differences between groups in relapse to 
any substance. Most of the between-group effect sizes for neurocognitive measures and 
functional assessments had 95% confidence intervals that crossed zero. Some significant 
between-group effect sizes were found for certain neurocognitive measures (attentional bias, 
attention, visual memory, executive function) and one functional assessment (Drug User Quality 
of Life Scare). 
Based on this pilot trial’s feasibility, acceptability, and preliminary effect sizes, we believe 
a definitive RCT is warranted. Key elements of this definitive RCT include having adequate 
sample size and power to test the efficacy of the interventions, selecting a priori primary and 
secondary outcomes, refining the content of the Control arm homework assignments to improve 
homework completion percentage, decreasing the number of assessments to limit participant 
burden (e.g., limiting neurocognitive assessments to 1 hour, removing neurocognitive 
assessments that are too similar to the computer exercises), decreasing the number of hours of 
computer exercises to limit participant burden, blinding research staff who assess outcomes, 
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concealing the randomization sequence from research staff, using other contingency 
management techniques for motivation instead of cash, selecting a more standardized control 
intervention, and implementing interim analyses and stopping rules. The third and final paper 
will be a secondary analysis of the Multiple Errands Test as associated with the neurocognitive 
assessments. 
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Table 2.1. Baseline Sociodemographics and Clinical Characteristics. 
 
*Mean (Standard Deviation) ^n (%) 
 
Measure 
Cog-Rehab Arm 
(n = 16) 
Control Arm 
(n = 15) 
Age in years* 57.2 (3.9) 57.9 (7.4) 
Male^ 16 (100%) 14 (93.3%) 
Black^ 8 (50%) 11 (73.3%) 
White^ 8 (50%) 4 (26.7%) 
American Indian/Alaska Native^ 5 (31.3%) 2 (13.3%) 
Latino^ 4 (25%) 2 (13.3%) 
Single/Never Married^ 7 (43.8%) 8 (53.3%) 
Divorced^ 7 (43.8%) 6 (40%) 
Education in years* 12.6 (1.3) 13.1 (1.4) 
Retired/Disability over past 3 years^ 13 (81.3%) 13 (86.7%) 
Right-handed^ 12 (75%) 14 (93.3%) 
Cocaine – age in years when first tried* 19.9 (6.1) 24.7 (9.9) 
Cocaine – age in years of regular use* 
(started using 3x/week or more) 
22.9 (5.5) 28.9 (9.0) 
Cocaine – net years used* 
(total years used minus abstinence) 
21.9 (9.2) 21.8 (10.0) 
MINI (Mini-International Neuropsychiatric Interview) 
depressive disorder current diagnosis^ 
2 (12.5%) 2 (13.3%) 
MINI depressive disorder past diagnosis^ 12 (75%) 6 (40%) 
MINI depressive disorder recurrent diagnosis^ 9 (56.3%) 6 (40%) 
MINI PTSD (Posttraumatic Stress Disorder) 
current diagnosis^ 
6 (37.5%) 7 (46.7%) 
MINI alcohol use disorder 
past 12 months diagnosis^ 
6 (37.5%) 2 (13.3%) 
MINI cannabis use disorder 
past 12 months diagnosis^ 
5 (31.3%) 2 (13.3%) 
MINI opioid use disorder 
past 12 months diagnosis^ 
6 (37.5%) 5 (33.3%) 
Prescribed methadone 
as part of opioid treatment program^ 
5 (31.3%) 7 (46.7%) 
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Table 2.2. Acceptability Assessments at End of Treatment. 
 
   CSUQ = Computer System Usability Questionnaire     GTQ = Game Training Questionnaire    
       *Mean (Standard Deviation)           ^n (%)  
         For statistical analyses for each measure between groups, the point estimate, 
         the confidence interval, and the P-value are listed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 End of Treatment 
Measure 
Cog-Rehab Arm 
(n = 16) 
Control Arm 
(n = 15) 
CSUQ – overall satisfaction score* 
1.9 (1.3) 2.0 (1.5) 
t(29) = -0.1; -1.1 to 1.0; P = 0.90 
CSUQ system usefulness score* 
2.0 (1.3) 2.1 (1.5) 
t(29) = -0.2; -1.1 to 0.9; P = 0.84 
CSUQ information quality score* 
2.0 (1.3) 2.0 (1.6) 
t(29) = 0.01; -1.1 to 1.1; P = 1.0 
CSUQ interface quality score* 
1.9 (1.4) 2.0 (1.7) 
t(29) = -0.2; -1.2 to 1.0; P = 0.88 
GTQ #2 – Question #1 (enjoyable)^ 
13 (81.3%) agree 9 (60%) agree 
Fisher’s exact p = 0.19 
GTQ #2 – Question #2 (challenging)^ 
9 (56.3%) agree 10 (66.7%) agree 
Fisher’s exact p = 0.40 
GTQ #2 – Question #3 (frustrated)^ 
5 (31.3%) agree 2 (13.3%) agree 
Fisher’s exact p = 0.20 
GTQ #2 – Question #4 (motivated)^ 
10 (62.5%) agree 9 (60%) agree 
Fisher’s exact p = 0.06 
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Chapter 3 Abstract 
Background: The Multiple Errands Test (MET) is an interviewer-administered measure used to 
assess real-world cognitive functional performance based on completing a series of tasks 
outside of the traditional office setting. Tasks include purchasing an item, writing the names of 
items, and finding the price of items. These tasks are to be completed under a set of rules, such 
as spending as little money as possible and doing the tasks in any order. The MET has 
undergone various revisions since it was originally created. The MET version used in this study, 
the MET-Revised (MET-R), uses more objective scoring metrics by raters than the traditional 
MET. Whereas the MET includes metrics such as “inefficiencies”, “strategies”, and 
“interpretation failures” that are more open to subjective impressions when scored by raters, the 
MET-R instead has scoring metrics such as “number of locations visited”, “number of tasks 
completed”, and “number of rule breaks” that are more objective when scored by raters. The 
MET has been used in substance use disorder population and has been found to have small 
associations with the executive function domain when compared with traditional neurocognitive 
measures. It is unclear whether the difference in scoring metrics between the MET and the 
MET-R means that the various revisions of the MET are assessing different cognitive domains. 
Understanding on what cognitive domains the MET-R maps may be helpful in using the MET-R 
as a more time-efficient way to assess cognition in substance use disorder populations, 
compared to a lengthy neurocognitive battery. 
Aim: The aim of this study was to assess whether performance on the MET-R by adult veterans 
with a primary cocaine use disorder is associated with domains of attention, memory, executive 
function, and impulsivity on a comprehensive neurocognitive battery. Similar to the MET, we 
hypothesized that MET-R performance would be more strongly correlated with the domain of 
executive function than the domains of attention, memory, or impulsivity. 
Methods: This paper is a secondary analysis of data from a pilot clinical trial (n = 31), where the 
MET-R was administered along with a comprehensive neurocognitive battery. The measures 
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from the neurocognitive battery were organized into four domains (attention, memory, executive 
function, impulsivity) and nine sub-domains. For the linear regression model, the outcome 
variable was baseline MET-R performance efficiency T-score, and the predictor variable was 
baseline neurocognitive domain or sub-domain composite T-score. All neurocognitive measures 
were adjusted for age, sex, and education. The model was also adjusted for age in years of 
regular cocaine use. 
Results: Study participants had a mean age of 57.5 years (SD 5.8), 30 (96.8%) were male, 19 
(61.3%) were Black, 12 (38.7%) were White, 6 (19.4%) were Latino, 15 (48.4%) were single, 
and had a mean education of 12.8 years (SD 1.4). The mean composite T-scores for 
neurocognitive subdomains were as low as 33 (SD 8.1) for the verbal memory sub-domain and 
as high as 49.3 (SD 7.4) for the decision-making sub-domain. MET-R performance was 
significantly associated only with the overall impulsivity neurocognitive domain (adjusted 
coefficient 0.8, 95% CI 0.2 to 1.3) but no other domains. 
Conclusion: This is the first paper to assess MET-R performance in a sample of persons with 
substance use disorders. MET-R performance was significantly associated only with the overall 
impulsivity neurocognitive domain but no other domains. The MET-R may be uniquely 
measuring the domain of impulsivity that is not captured by traditional neurocognitive testing. 
The MET-R will need testing in larger samples of persons with substance use disorders to 
determine whether it is clinically meaningful or correlated with other health outcomes. 
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Chapter 3 Main Body 
INTRODUCTION 
Cognitive impairment in those with substance use disorders (SUDs) [363-367] is 
associated with relapse [368, 369], lower likelihood of treatment completion [370-374], lower 
motivation [375], and worse quality of life [376, 377]. Effectively treating cognitive impairment as 
part of a comprehensive treatment plan for CUD could potentially improve important clinical 
outcomes, such as abstinence, quality of life, and treatment completion. 
While assessment of cognition through traditional comprehensive neurocognitive 
batteries is ideal [378], these batteries can take several hours and lead to significant burden and 
fatigue for patients in a clinical setting and participants in a clinical research setting. In addition, 
such batteries may not be ecologically valid, as structured neurocognitive batteries in a research 
setting may not capture the unstructured nature of cognitive demands in everyday real-world 
tasks [379]. To address the shortcomings of traditional neurocognitive batteries, different types 
of unstructured tests have been created in an attempt to better capture the cognitive demands 
of everyday activities in real-world settings [379]. Examples include the Twenty Questions from 
the Delis-Kaplan Executive Function System, the Rivermead Behavioural Memory Test-Third 
Edition [379], and the Multiple Errands Test [380].  
The Multiple Errands Test (MET) is a 30-40 minute interviewer-administered measure 
used to assess real-world cognitive functional performance based on completing a series of 
tasks outside of the traditional office setting [380]. Tasks include purchasing an item, writing the 
names of items, and finding the price of items. These tasks are to be completed under a set of 
rules, such as spending as little money as possible and doing the tasks in any order. The MET 
has been used in various populations, such as persons with brain injury [381, 382], multiple 
sclerosis [383], Parkinson’s disease [384], stroke [385], bipolar disorder [386], schizophrenia 
[387], obsessive-compulsive disorder [388], and substance use disorders [389]. The MET has 
undergone various revisions since it was originally created, such as the virtual MET [388], the 
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MET Hospital Version [390], the Chinese MET [391], the Big-Store MET [392], the MET 
Simplified Version [393], the MET Home Version [394], and the MET-Revised (MET-R) [385].  
The MET has been used in substance use disorder populations [395, 396] and has been 
found to have small associations with the executive function domain [389] when compared with 
traditional neurocognitive measures. For example, in a study of 60 participants with alcohol, 
cocaine and heroin use disorders [389], the largest Pearson’s correlations were -0.34 for task 
failures and the Letters and Numbers Test, and -0.31 for interpretation failures and the Zoo Map 
Test. However, the MET-R (also estimated to be 30-40 minutes in length) uses slightly different 
scoring metrics than the traditional MET. Whereas the MET includes metrics such as 
“inefficiencies”, “strategies”, and “interpretation failures” that are more open to subjective 
impressions when scored by raters, the MET-R instead has scoring metrics such as “number of 
locations visited”, “number of tasks completed”, and “number of rule breaks” that are more 
objective when scored by raters. The MET-R was specifically developed to provide an objective 
scoring system for raters [385] compared to the MET. It is unclear whether this difference in 
scoring metrics between the MET and the MET-R means that the various revisions of the MET 
are assessing different cognitive domains. Understanding on what cognitive domains the MET-
R maps may be helpful in using the MET-R as a more time-efficient way to assess cognition in 
substance use disorder populations, compared to a lengthy neurocognitive battery which can 
take up to 2-3 hours. 
The aim of this study was to assess whether performance on the MET-R by adult 
veterans with a primary cocaine use disorder is associated with domains of attention, memory, 
executive function, and impulsivity on a comprehensive neurocognitive battery. This paper is a 
secondary analysis of data from a pilot clinical trial (n = 31), where the MET-R was administered 
at baseline along with a comprehensive neurocognitive battery. Similar to the MET, we 
hypothesized that MET-R performance would be more strongly correlated with the domain of 
executive function than the domains of attention, memory, or impulsivity. 
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METHODS 
Overall Study Design 
The data used for this analysis came from a randomized, parallel-group outpatient study 
of treatment-seeking adult veterans with a primary cocaine use disorder and cognitive 
impairment. The full details of the study have been described in a previous paper (see Chapter 
#1). 
Study Setting 
This study was conducted at the San Francisco Veterans Affairs Health Care System 
(SFVAHCS) between 7/1/2014 and 6/30/2019. This study was registered on clinicaltrials.gov 
(NCT01684293). This study was approved by both the University of California, San Francisco 
(UCSF) Institutional Review Board (IRB) and the SFVAHCS Clinical Research Workgroup. All 
participants were paid in cash (US dollars) for their study participation ($15 for each study visit). 
The funding source (National Institute on Drug Abuse) had no role in the design of this study 
and had no role during its execution, analyses, interpretation of the data, or decision to submit 
results. 
Study Recruitment 
Word-of-mouth and flyers around the SFVAHCS were used to recruit potential 
participants. Participants signed a written informed consent form to participate. 
Neurocognitive Measures 
The full list of measures is described in a previous paper (see Chapter #1). This study 
was especially relevant for this analysis, because neurocognitive measures and the MET-R 
were collected at baseline. The neurocognitive measures were organized into four 
neurocognitive domains (attention, memory, executive function, impulsivity) and nine sub-
domains (Table 3.1). All measures were adjusted for age, sex, and education, and all measures 
were converted to T-scores (mean = 50, SD = 10, range 0 to 100) before creating composite 
scores for each neurocognitive domain and sub-domain. 
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Attention neurocognitive assessments included the Delis–Kaplan Executive Function 
System (D-KEFS) Trail Making Test (Conditions 1, 2, 3, and 5), and Wechsler Adult Intelligence 
Scale Fourth Edition (WAIS-IV) Coding and Symbol Search. For the D-KEFS [397], scaled 
scores were converted to T-scores. The WAIS-IV [398] Coding and Symbol Search scaled 
scores were converted to T-scores. The attention domain was divided into a visual attention 
sub-domain (D-KEFS Trail Making Test) and a processing speed sub-domain (WAIS-IV Coding 
and Symbol Search). 
Memory neurocognitive assessments included the WAIS-IV Digit Span and Arithmetic, 
Hopkins Verbal Learning Test-Revised (HVLT-R), and Brief Visuospatial Memory Test-Revised 
(BVMT-R). The WAIS-IV [398] Digit Span and Arithmetic scaled scores were converted to T-
scores. For the HVLT-R [399, 400] and BVMT-R [401], T-scores were calculated from the raw 
scores. The memory domain was divided into a working memory sub-domain (WAIS-IV Digit 
Span and Arithmetic), a verbal memory sub-domain (HVLT-R), and a visuospatial memory sub-
domain (BVMT-R). 
Executive function neurocognitive assessments included the D-KEFS Tower Test, D-
KEFS Trail Making Test (Condition 4), D-KEFS Color-Word Interference Test, and Wisconsin 
Card Sorting Test (Computer Version 4) [WCST]. The scaled scores for the D-KEFS tests were 
converted to T-scores. For the WCST [402, 403], T-scores were calculated from the raw scores. 
The executive function domain was divided into a cognitive flexibility sub-domain (D-KEFS 
Tower Test, Trail Making Test, and Color-Word Interference Test) and a set shifting sub-domain 
(WCST). 
Impulsivity neurocognitive assessments included the Conners’ Continuous Performance 
Test (CPT) 3rd Edition and the Iowa Gambling Task (IGT). For the computerized CPT [404], T-
scores were calculated from the raw scores. For this analysis, the T-scores were reverse-scored 
to ensure that a higher T-score means better performance. For the computerized IGT [405], T-
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scores were calculated from the raw scores. The impulsivity domain was divided into a 
continuous performance sub-domain (Conners’ CPT) and a decision-making sub-domain (IGT). 
MET-R Description and Procedure 
Because the MET is administered in real-world settings, local versions have to be 
developed since each setting is unique and no two real-world settings are exactly alike. The 
MET is an example of a performance-based test that requires performing tasks in a setting of 
unpredictability, interpersonal interactions, social demands, noise, and little or no assistance 
from the staff administering the test [385, 406, 407]. The MET-R was specifically developed to 
provide an objective scoring system for raters [385] compared to the MET. The MET-R used in 
this study was adapted to the SFVAHCS. Adaptation means that a map of the SFVAHCS had to 
be created for participants to use (Figure 3.1), and tasks that could be completed at the 
SFVAHCS based on the SFVAHCS environment had to be created (Figure 3.2). There are no 
previous reliability and validity data on the MET-R at the SFVAHCS since this version was 
newly adapted for this study.  
A map of the SFVAHCS is given to each participant (Figure 3.1). This map contains a 
key of locations around the SFVAHCS where participants can complete the necessary tasks. 
The participant is given an instruction sheet of the tasks to complete (Figure 3.2). Tasks include 
mailing an item, purchasing items, making a phone call, obtaining answers to questions, 
meeting the examiner at a certain place and time, and talking to the staff person after 
completing certain tasks. This instruction sheet also contains a list of rules to follow while 
completing the tasks. Rules include not spending more than a certain dollar amount, not going 
back into a previously visited area, not buying more than 2 items at a location, and not speaking 
to the staff person unless it is part of the exercise. 
The participant is also provided with a sports watch to wear during the test which tracks 
distance traveled while walking around the SFVAHCS, number of calories burned while walking 
around the SFVAHCS, and number of steps taken while walking around the SFVAHCS. The 
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participant is also given a clipboard, pen, stamp, and a $10-bill. The staff person administering 
the MET-R follows behind the participant around the SFVAHCS with a stopwatch, pen, 
clipboard, and a recording and scoring sheet (Figure 3.3). The recording and sheet contain 
items that the staff person has to complete as the participant is doing the test and after the 
participant finishes the test. Items to record include the number of locations visited, the number 
of items completed, and the number of rules broken. 
The MET-R scores include distance traveled while walking around the SFVAHCS, 
number of calories burned while walking around the SFVAHCS, number of steps taken while 
walking around the SFVAHCS, total completion time, number of locations visited, number of 
tasks completed, and number of rule breaks. A performance efficiency score was calculated 
(total tasks completed / total locations visited). For this paper, the performance efficiency score 
was determined to be the key outcome of interest. The performance efficiency score was 
converted to a T-score. 
Blinding 
 Ideally, those who assessed the primary outcomes would be blinded to the study arm. 
However, since this was a pilot study with limited funding through a career development award 
and turnover of non-permanent research assistants during the study period, outcomes were 
assessed by whichever staff was practically available to assess the outcomes at a given study 
visit. 
Adherence/Quality Assurance 
All participants came to the SFVAHCS to complete all visit tasks. A Standard Operating 
Procedure (SOP) manual for the neurocognitive testing and the MET-R was created for 
research staff. Research assistants were trained on all tasks and supervised by the principal 
investigator. Research staff were trained on materials needed, organization of materials, pre-
test administration procedures, verbal scripts to read to participants, test administration 
procedures, end of test administration procedures, post-test administration procedures, and 
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scoring procedures. The principal investigator personally observed all research assistants 
performing all neurocognitive testing and MET-R administration on at least 3 participants 
initially. All research assistants were expected to finish scoring the same day of test 
administration. Scoring of all measures on all participants was double-checked by the principal 
investigator, and any errors or discrepancies were immediately corrected. All participants’ charts 
(no specific sampling plan) were audited yearly for data integrity by the principal investigator 
and the SFVAHCS research compliance officer. 
Statistical Analysis 
Stata/SE 16.1 (update level 5/20/2020) was used for all descriptive and linear regression 
analyses. Standard descriptive statistics were used to summarize MET-R performance (e.g., 
mean, standard deviation). For the linear regression model, the outcome variable was baseline 
MET-R performance efficiency T-score, and the predictor variable was baseline neurocognitive 
domain or sub-domain composite T-score. All neurocognitive measures were adjusted for age, 
sex, and education. The model was also adjusted for age in years of regular cocaine use 
(started using 3x/week or more), since Control arm participants were significantly older when 
they became regular cocaine users (age 29) than Cog-Rehab arm participants (age 23) [t(29) = 
-2.2; -11.4 to -0.5; P = 0.03]. 
Linear regression models were checked for linearity, normality, constant variance 
(homoscedasticity), outlying/high leverage/influential points, and multicollinearity. Linearity was 
assessed using component plus residual (CPR) plots with the LOWESS smooth option. 
Normality was assessed using quantile plots of residuals against the quantiles of the normal 
distribution (qnorm), kernel density plots of the residuals (kdensity), and the ladder-of-powers 
quantile-normal plots (qladder). Constant variance was assessed by residual versus predictor 
(RVP) plots of continuous predictors and residual versus fitted (RVF) plots. To account for 
heteroskedasticity, heteroskedasticity consistent (hc3) standard errors were used [408-410]. 
Outlying/high leverage/influential points were assessed using boxplots to detect outlying values 
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among the dfbetas; no observations had absolute dfbetas greater than 2. Multicollinearity was 
assessed analyzing the variance inflation factor values after each regression model; no 
observations had values greater than 10. 
RESULTS 
Participant Characteristics 
Overall, study participants had a mean age of 57.5 years (SD 5.8), 30 (96.8%) were 
male, 19 (61.3%) were Black, 12 (38.7%) were White, 6 (19.4%) were Latino, 15 (48.4%) were 
single, and had a mean education of 12.8 years (SD 1.4). Participants in both groups (Table 
3.2) were similar in sex, age, education, race, ethnicity, marital status, retirement status, and 
handedness. Control arm participants were significantly older when they became regular 
cocaine users (age 29) than Cog-Rehab arm participants (age 23) [t(29) = -2.2; -11.4 to -0.5; P 
= 0.03]. Participants in both groups had similar psychiatric diagnoses. 
Summary Statistics of Neurocognitive Domains and MET-R 
 The mean composite T-scores for neurocognitive domains (Table 3.3) were as low as 33 
(SD 8.1) for the verbal memory sub-domain and as high as 49.3 (SD 7.4) for the decision-
making sub-domain. Regarding the MET-R (Table 3.3), the mean time of completion was 19.9 
minutes (SD 5), the mean number of tasks completed was 8.4 (SD 1.9), the mean number of 
locations visited was 13.3 (SD 4.1), the mean number of rule breaks was 4.7 (SD 1.6), and the 
mean performance efficiency T-score was 50 by definition. 
Association between MET-R Performance Efficiency T-Score and Neurocognitive Domain 
Composite T-Scores 
Normality, constant variance, outlying/high leverage/influential points, and 
multicollinearity assumptions for the linear regression models were met (Figure 3.4). For the 
linearity assumption, there was noise in the tails for the neurocognitive domain composite T-
scores, but such noise is not unexpected for a study with a small sample size. 
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The 95% confidence intervals for most of the adjusted coefficients crossed 0 (Table 3.4). 
However, MET-R performance was significantly associated with the overall impulsivity 
neurocognitive domain (adjusted coefficient 0.8, 95% CI 0.2 to 1.3). Though not statistically 
significant, the continuous performance sub-domain had an adjusted coefficient of 0.4, and the 
adjusted coefficient was 0.3 for the decision-making sub-domain, overall executive function 
domain, cognitive flexibility sub-domain, overall memory domain, and verbal memory sub-
domain. 
DISCUSSION 
This is the first paper to assess MET-R performance in a sample of persons with 
substance use disorders. In a sample of veterans with a primary cocaine use disorder, MET-R 
performance was significantly associated only with the overall impulsivity neurocognitive domain 
(adjusted coefficient 0.8, 95% CI 0.2 to 1.3) but no other domains. Though the impulsivity sub-
domains were not significant, perhaps the overall impulsivity domain being significant was due 
to elimination of noise when taking the average of the impulsivity sub-domains and creating an 
overall impulsivity domain score. 
To our knowledge, other versions of the MET [381, 384, 411] and the previous study of 
participants with alcohol, cocaine and heroin use disorders [389] have focused on the executive 
function domain but have not separately assessed the domain of impulsivity. Perhaps the 
objective scoring nature of the MET-R, as opposed to the scoring of the MET that is more 
subject to interpretation depending on the rater, is tapping into the overall impulsivity domain 
more than other domains. Since MET-R performance is defined as tasks/locations, perhaps an 
association with overall impulsivity means that participants are simply performing more tasks in 
a frantic manner due to the unstructured nature of the MET-R. Participants may be performing 
more tasks chaotically without any upfront plan. This explanation will need to be further explored 
in a larger study with more power. 
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 Though the associations with other neurocognitive domains and sub-domains were not 
statistically significant, the adjusted coefficients were in the 0.3 to 0.4 range. This study only had 
power to detect overall large effects (e.g., Cohen’s F-squared = 0.35; Cohen’s d = 1.04; 
Cohen’s q = 1.12). Perhaps other neurocognitive domains and sub-domains would become 
statistically significant in a larger study with more power, and the clinical significance of such 
statistical findings will need to be explored in this larger study. The MET-R will also need further 
testing in larger samples of persons with substance use disorders to establish comparability with 
neurocognitive measures. If the MET-R performance is indeed captured by several cognitive 
domains than just one domain (such as executive function or impulsivity), the MET-R could 
potentially be a more time-efficient way to assess cognition (mean 19.9 minutes [SD 5] in this 
study) than a lengthy neurocognitive battery which can take up to 2-3 hours. 
Strengths 
First, this study collected a comprehensive set of neurocognitive measures, which 
allowed for the investigation of the association between neurocognitive domains and MET-R 
performance. Second, we conducted this study at a veteran’s hospital in patients with complex 
comorbidities in an effort to maximize internal validity for this little-studied population. Finally, 
the MET-R is a relatively low technology measure to implement by research staff with a college 
degree. 
Limitations 
 First, the sample size for this analysis was small, and this study is underpowered. The 
results are perhaps false-negative due to the small sample size. A larger sample size will be 
needed to better tease out which neurocognitive domains may be best associated with MET-R 
performance. Second, most community-based addiction treatment programs will not have 
access to extensive neurocognitive assessments as conducted in this study, which limits the 
detailed assessment of various cognitive domains in patients treated in a community setting.  
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Third, a more rigorous program of training research assistants with formal proficiency 
checks could have been implemented. Since this was a pilot study, the principal investigator 
was able to double-check all of the research assistants’ work. This level of double-checking may 
not be possible in a larger trial, and this limitation will need to be addressed in a larger study. 
Finally, despite the inherent unpredictability in performance-based tests like the MET-R and 
local versions needing to be developed due to the uniqueness of each setting, the MET-R that 
was adapted to the SFVAHCS will still need independent reliability and validity testing in a 
separate study due to psychometric concerns. 
CONCLUSION 
In a sample of veterans with a primary cocaine use disorder, MET-R performance was 
significantly associated only with the overall impulsivity neurocognitive domain but no other 
domains. The MET-R may be uniquely measuring the domain of impulsivity that is not captured 
by traditional neurocognitive testing. The MET-R will need testing in larger samples of persons 
with substance use disorders to determine whether it is clinically meaningful or correlated with 
other health outcomes. The MET-R could potentially become a more time-efficient way to 
assess cognition in outpatient clinical settings and community-based addiction treatment 
programs, rather than a lengthy neurocognitive battery. 
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Figure 3.1. Multiple Errands Test-Revised Map. 
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Figure 3.2. Multiple Errands Test-Revised Instruction Sheet. 
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Figure 3.3. Multiple Errands Test-Revised Recording and Scoring Sheet. 
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Table 3.2. Participant Characteristics. 
 
*Mean (Standard Deviation) ^n (%) 
 
Measure 
Cog-Rehab Arm 
(n = 16) 
Control Arm 
(n = 15) 
Age in years* 57.2 (3.9) 57.9 (7.4) 
Male^ 16 (100%) 14 (93.3%) 
Black^ 8 (50%) 11 (73.3%) 
White^ 8 (50%) 4 (26.7%) 
American Indian/Alaska Native^ 5 (31.3%) 2 (13.3%) 
Latino^ 4 (25%) 2 (13.3%) 
Single/Never Married^ 7 (43.8%) 8 (53.3%) 
Divorced^ 7 (43.8%) 6 (40%) 
Education in years* 12.6 (1.3) 13.1 (1.4) 
Retired/Disability over past 3 years^ 13 (81.3%) 13 (86.7%) 
Right-handed^ 12 (75%) 14 (93.3%) 
Cocaine – age in years when first tried* 19.9 (6.1) 24.7 (9.9) 
Cocaine – age in years of regular use* 
(started using 3x/week or more) 
22.9 (5.5) 28.9 (9.0) 
Cocaine – net years used* 
(total years used minus abstinence) 
21.9 (9.2) 21.8 (10.0) 
MINI (Mini-International Neuropsychiatric Interview) 
depressive disorder current diagnosis^ 
2 (12.5%) 2 (13.3%) 
MINI depressive disorder past diagnosis^ 12 (75%) 6 (40%) 
MINI depressive disorder recurrent diagnosis^ 9 (56.3%) 6 (40%) 
MINI PTSD (Posttraumatic Stress Disorder) 
current diagnosis^ 
6 (37.5%) 7 (46.7%) 
MINI alcohol use disorder 
past 12 months diagnosis^ 
6 (37.5%) 2 (13.3%) 
MINI cannabis use disorder 
past 12 months diagnosis^ 
5 (31.3%) 2 (13.3%) 
MINI opioid use disorder 
past 12 months diagnosis^ 
6 (37.5%) 5 (33.3%) 
Prescribed methadone 
as part of opioid treatment program^ 
5 (31.3%) 7 (46.7%) 
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